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Cytokine Networks In Esophageal Squamous Cell Carcinoma
Abstract
Esophageal cancer is one of the top reasons for cancer-related deaths worldwide, and esophageal
squamous cell carcinoma (ESCC) accounts for up to 90% of all esophageal cancer cases. One of the
major reasons for the high mortality rate is the lack of targeted therapies for ESCC, particularly for
advanced stage disease. The tumor microenvironment (TME) is a complex system of multiple cell types
(fibroblasts, immune cells, blood and lymphatic vessels, etc.) that supports tumor growth in various ways.
We aimed to investigate some of the mechanisms of dynamic interaction between tumor cells and TME
components and to identify approaches to targeting these interactions therapeutically.
Desmoplasia, or deposition of connective tissue components (fibroblasts and extracellular matrix (ECM)),
is a pronounced histological feature of ESCC. Previous research from the Rustgi lab and others has
underscored the importance of cancer-associated fibroblasts (CAFs) and ECM components for ESCC
progression. We have identified two cytokines that mediate these effects: IL-6 and RANTES. Through in
vitro studies we have confirmed the relevance of these cytokines to human ESCC and determined that
they function mostly through activation of STAT3 and ERK1/2 signaling pathways. We have also validated
IL-6 and RANTES as novel targets for ESCC therapy by using tocilizumab (human IL-6R antibody) and
maraviroc (CCR5 inhibitor) to inhibit the growth of subcutaneous ESCC xenotransplants in vivo.
Chronic inflammation and immunosuppressive microenvironment are also essential contributors to ESCC
pathogenesis. We have identified the ectoenzyme-receptor CD38 as a driver of expansion of myeloidderived suppressor cells in several murine models of ESCC. We have also identified six cytokines (IFNγ,
TNFα, CXCL16, IGFBP-3, IL-6 and RANTES) as promoters of CD38 expression by these cells in vitro. To
determine whether CD38 is a valuable target for therapy, we have utilized a neutralizing antibody to CD38
to suppress tumor growth in a syngeneic murine model of ESCC.
In summary, we have identified novel mechanisms of interaction between tumor cells, CAFs and myeloidderived suppressor cells in esophageal TME. Furthermore, we have tested three independent in vivo
approaches to therapeutic targeting of these mechanisms that can potentially improve the clinical
outcomes of ESCC treatment.
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ABSTRACT
CYTOKINE NETWORKS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Tatiana Karakasheva
Anil K. Rustgi
Esophageal cancer is one of the top reasons for cancer-related deaths
worldwide, and esophageal squamous cell carcinoma (ESCC) accounts for up to 90% of
all esophageal cancer cases. One of the major reasons for the high mortality rate is the
lack of targeted therapies for ESCC, particularly for advanced stage disease. The tumor
microenvironment (TME) is a complex system of multiple cell types (fibroblasts, immune
cells, blood and lymphatic vessels, etc.) that supports tumor growth in various ways. We
aimed to investigate some of the mechanisms of dynamic interaction between tumor
cells and TME components and to identify approaches to targeting these interactions
therapeutically.
Desmoplasia, or deposition of connective tissue components (fibroblasts and
extracellular matrix (ECM)), is a pronounced histological feature of ESCC. Previous
research from the Rustgi lab and others has underscored the importance of cancerassociated fibroblasts (CAFs) and ECM components for ESCC progression. We have
identified two cytokines that mediate these effects: IL-6 and RANTES. Through in vitro
studies we have confirmed the relevance of these cytokines to human ESCC and
determined that they function mostly through activation of STAT3 and ERK1/2 signaling
pathways. We have also validated IL-6 and RANTES as novel targets for ESCC therapy
by using tocilizumab (human IL-6R antibody) and maraviroc (CCR5 inhibitor) to inhibit
the growth of subcutaneous ESCC xenotransplants in vivo.
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Chronic inflammation and immunosuppressive microenvironment are also
essential contributors to ESCC pathogenesis. We have identified the ectoenzymereceptor CD38 as a driver of expansion of myeloid-derived suppressor cells in several
murine models of ESCC. We have also identified six cytokines (IFNγ, TNFα, CXCL16,
IGFBP-3, IL-6 and RANTES) as promoters of CD38 expression by these cells in vitro. To
determine whether CD38 is a valuable target for therapy, we have utilized a neutralizing
antibody to CD38 to suppress tumor growth in a syngeneic murine model of ESCC.
In summary, we have identified novel mechanisms of interaction between tumor
cells, CAFs and myeloid-derived suppressor cells in esophageal TME. Furthermore, we
have tested three independent in vivo approaches to therapeutic targeting of these
mechanisms that can potentially improve the clinical outcomes of ESCC treatment.
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Chapter 1 CHAPTER 1: Introduction
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Esophageal squamous cell carcinoma
Esophageal cancer is a major cause of cancer-related death worldwide: 455,800
new cases were reported and 400,200 deaths occurred from this disease in 2012 (Torre
et al., 2015). There are two major subtypes of esophageal cancer: esophageal
squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), and while
the latter is more prevalent in North America and Europe, ESCC is the subtype that
accounts for 90% of all esophageal cancers worldwide (Rustgi and El-Serag, 2014).
According to the SEER database, 16,910 new cases (1% of all cancers) and 15,690
deaths (2.6% of all cancer-related deaths) are predicted to occur in the US in 2016
(Howlader N, et al., 2016).
Over the past three decades, there was a significant increase in overall median
survival (from 6 months in 1970s to 10 months in 2000s) and 5-year survival rate (9% to
22%). However, these improvements can be attributed almost exclusively to advances in
early detection: increased survival was seen mostly in patients with localized disease
and to a lesser extent in patients with regional disease (Njei et al., 2016). The use of
surgery and neoadjuvant chemoradiation therapy have also increased, implying that
targeted use of these treatment approaches also contributed to improved survival.
Importantly, when ESCC and EAC data were analyzed separately, it became clear that
the increased survival has been achieved for EAC only. Therefore, despite rising
incidence, these patients have better long-term survival prognosis than patients with
ESCC (Njei et al., 2016). These data clearly indicate a need for better understanding of
the biology of, and novel therapeutic options for, ESCC.
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Though both types of cancer arise in the same organ, ESCC and EAC are in fact
distinctly different diseases. In addition to different histology and long-term survival
statistics described above, they even arise in different parts of the esophagus: ESCC
occurs in the lower and mid-esophagus, while EAC is most common in the distal part
(Napier et al., 2014). The risk factors for the two subtypes are also distinct: alcohol and
tobacco use, particularly in synergy, are most strongly associated with ESCC, while
gastroesophageal reflux disease (GERD), obesity (particularly the visceral fat) and
alcohol consumption (less strongly than for ESCC) are the major risk factors for EAC
(Rustgi and El-Serag, 2014). Finally, genetic risk factors differ as well between the two
disease: mutations in the TP53, RB1, CDKN2A, PIK3CA, NOTCH1, NFE2L2, ADAM29
and FAM135B genes are most frequent in ESCC (Song et al., 2014), while TP53,
CDKN2A, SMAD4, ARID1A, and PIK3CA mutations occur most often in EAC (Dulak et
al., 2013).
The tumor microenvironment
Historically, investigation of cancer biology initially focused on the tumor cell: its
physiology, genetic (and later epigenetic) profiles, and signaling pathways. The first
generations of cancer therapeutics were developed based on this research. Yet, despite
all the breakthrough discoveries in those areas, clinical oncology still faces major
obstacles – from the toxicity induced by early chemotherapeutic agents to development
of chemo- and radioresistance, resistance to diverse targeted therapeutics, and tumor
metastases, all of which stand in the way of developing effective cures for cancer.
The concept of tumor microenvironment (TME) first gained attention in the late
XIX century, when Stephen Paget developed his “seed and soil” theory. Dr. Paget’s
3

observation that “when a plant goes to seed, its seeds are carried in all directions, but
they can only live and grow if they fall on congenial soil” (Paget, 1889) prompted the
medical community to take a closer look at the “soil” that allowed the tumor to establish
and progress. Sadly, this hypothesis and the exciting research that it invited laid dormant
for almost a century, possibly due to the fact that Dr. Paget’s views contradicted the then
predominant opinion, according to which the cancer cell, once carried by blood or lymph
to a distant organ, can remodel that site to suit its needs for successful metastasis.
Only in the 1970s was the “seed and soil” hypothesis revisited, this time gaining
the new appreciation (Witz, 2009). In his seminal editorial, Robert Auerbach wrote that
“In a time where the primary emphasis in cancer research is at the level of gene
expression, of regulation and of epigenetic modification of the "seed," those
individuals…, who study the properties of the host environment should not be ignored.
Not only are the observations of the 'soil' useful, they provide essential information
without which we will not be able to understand the nature of the metastatic process”
(Auerbach, 1988). Since then, a plethora of scientific reports have been published that
have helped to shape our understanding of the nature of the TME into what it currently
is: a complex system consisting of multiple cellular components (fibroblasts, multiple
immune cell subpopulations, microvasculature represented by endotheliocytes and
pericytes, adipocytes) and the extracellular matrix (ECM), which is a complex system of
biopolymers (polysaccharides such as proteoglycans and hyaluronic acid, collagen and
elastin fibers, fibronectins), matricellular proteins (non-structural proteins that can modify
the ECM, such as osteopontin, periostin and SPARC) and various growth factors and
cytokines (EGF, HGF, VEGF, TGFβ) embedded in this matrix. The “official status” of the
4

TME in the field of cancer research has been sealed, when its components have been
incorporated into the famous concept of “hallmarks of cancer” to underscore that “Most
of the hallmarks of cancer are enabled and sustained to varying degrees through
contributions from repertoires of stromal cell types and distinctive subcell types”
(Hanahan and Coussens, 2012).
In the early 1990s it became increasingly clear that a deeper understanding of
the TME’s dynamic nature and role in cancer progression was needed. For example, in
his keynote address to the attendees of the Third International Conference on the
Interaction of Radiation Therapy and Systemic Therapy in 1990, Ralph Durand stated
that “that the cellular microenvironment can play a major role in modifying the activity of
radiation and chemotherapy”, and he proceeded to suggest “some potential for new
treatment strategies designed specifically to exploit the tumor microenvironment”
(Durand, 1991). Later research proved Dr. Durand right: for example, increasing
evidence exists of chronic inflammation promoting chemoresistance via activation of
signaling pathways, most notably STAT3, in the tumor cells (Lee et al., 2014a; Spitzner
et al., 2014; Wörmann et al., 2016), while the cancer-associated fibroblasts (CAFs) are
also well known to promote resistance to therapy via multiple mechanisms, including
secreted factors (Meads et al., 2009), exosomes (Hu et al., 2015) and modifying cancer
cell metabolic pathways (Pavlides et al., 2009; Ying et al., 2012). Furthermore, CAFs
can affect the delivery of therapeutics to the tumor by affecting angiogenesis (Goel et al.,
2012) or the biophysical characteristics of the ECM (Provenzano et al., 2012).
One of the most fascinating features of the TME is its plasticity: unlike the cancer
cells, which acquire a whole portfolio of mutations as they evolve, the TME components
5

generally do not acquire mutations (Lee et al., 2014b; Witz, 2008). This implies that it
may be possible to educate the TME and de-differentiate its pro-tumorigenic
components back into their normal, anti-tumorigenic state.
The immune milieu in tumor microenvironment
The immune part of the TME comprises the cells belonging to the innate immune
system (macrophages, neutrophils, dendritic cells, mast cells and myeloid derived
suppressor cells), as well as effectors of the adaptive immunity (T and B lymphocytes).
Tumor associated macrophages (TAMs) are possibly the most common immune
cell subtype in the TME. Macrophages represent the terminal differentiation state of a
monocyte, which becomes adapted to residence within a certain organ. As is often the
case with immune cells, macrophages are a very heterogeneous group of cells, and
multiple classification schemes exist. The traditional approach is to subdivide the
macrophages into M1 and M2 subtypes. M1, or classically activated, macrophages are
generally induced by IFNγ and secrete high levels of pro-inflammatory cytokines (e.g.
TNFα, IL-6, IL-1, IL-12). By contrast, M2, or alternatively activated, macrophages can be
induced by IL-4, IL-10 or IL-13 secrete low levels of IL-12 and high levels of the antiinflammatory cytokine IL-10 (Grivennikov et al., 2010). However, both M2 and M1
macrophages remain fairly plastic. Most of the TAMs are M2, and can be further subcategorized into angiogenic, immunosuppressive, invasive, metastasis-associated,
perivascular, and activated macrophages (Komohara et al., 2016). TAMs have been
linked to numerous pro-tumorigenic processes, such as maintenance of chronic
inflammation in the TME, immunosuppression (direct or via activation of MDSCs),
angiogenesis, tumor cell invasion and metastasis, while in general, the presence of
6

TAMs in the tumor correlates with poor prognosis (Grivennikov et al., 2010; Komohara et
al., 2016). The classically activated M1 macrophages and dendritic cells, however, are
essential for antigen presentation and CTL activation, which are the cornerstone of antitumor immunity.
Historically, tumor-associated neutrophils (TANs) were considered to be a protumorigenic cell type (Fridlender and Albelda, 2012), and a number of studies
demonstrated a correlation between the presence of TANs and poor prognosis in
patients with melanoma, renal cancer, head and neck cancer and other cancer types
(Swierczak et al., 2015). However, recent studies have shed some light on the temporal
relationship between the tumor stage and the anti- or pro-tumorigenic capacity of
neutrophils. For example, in early stage human lung cancer TANs are able to activate
CTLs, but gradually loose this capacity at later stages (Eruslanov et al., 2014).
Myeloid-derived

suppressor

cells

(MDSCs)

originate

from

alternative

differentiation of normal immature myeloid progenitors under the influence of tumorderived factors. These are a very heterogeneous group of myeloid cells that are united in
their ability to suppress immune responses. MDSCs can be sub-divided further into the
monocytic (M-MDSC) and perimorphonuclear (PMN-MDSCs, or granulocytic MDSCs)
subsets based on their morphology and phenotype (Bronte et al., 2016). M- and PMNMDSCs employ different mechanisms for immunosuppression, and recent data suggest
that each subset’s immunosuppressive capacity also varies based on the location. For
example, PMN-MDSCs are the predominant subtype in peripheral lymphoid organs,
where they promote the development of tumor antigen-specific T cell tolerance. At the
same time, M-MDSCs tend to reside within the tumor and not only exert potent
7

immunosuppression (antigen-independent) function, but also rapidly differentiate into
TAMs (Kumar et al., 2016). In general, the direct association between the presence of
MDSCs and poor prognosis in cancer is well appreciated (Gabitass et al., 2011), and the
specifics of MDSCs in esophageal cancer will be addressed in detail in Chapter 3 of this
thesis.
T lymphocytes are also commonly found within the tumor, but unlike TAMs,
different T cell subtypes bear either pro-or anti-tumorigenic properties. For example, high
numbers of the CD8+ cytotoxic T lymphocytes (CTLs) or T helper 1 (Th1) cells can
correlate with increased survival (Mao et al., 2016). At the same time, another T cell
subset known as regulatory T cells (Treg) has widely appreciated pro-tumorigenic
properties. Tregs are a subtype of CD4+ cells that express the transcription factor
FoxP3, and their most investigated role in cancer is immunosuppression, which is
mediated by the cytokines IL-10, IL-35 and TGF-β (Grivennikov et al., 2010). Multiple
reports demonstrate a strong association between Treg infiltration and poor prognosis in
cancer patients (Chen et al., 2016; Mao et al., 2016).
The infiltration of B lymphocytes into tumor tissue is in general associated with
better prognosis, which can be mediated by more efficient antibody production or
antigen presentation (interestingly, B cells can be recruited to the tumor in response to
IFNγ production and tend to cluster with the CD8+ CTLs) (Guy et al., 2016; Mao et al.,
2016). Yet, similarly to T cells, a subset of B lymphocytes with immunoregulatory
capacity (Breg) has also been identified in murine models of cancer. Bregs are activated
by TGFβ and express the transcription factor FoxP3 (DiLillo et al., 2010). In human
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cancer, these cells are also associated with PD-1 mediated immunosuppression (Guan
et al., 2016).
Cytokines and pro-inflammatory signaling in cancer
As soluble factors that exist to mediate interactions between cells, the role of
various cytokines in cancer is well appreciated. In general, these factors act through
activation of numerous downstream effector pathways, such as STAT1/3, NF-κB, Smad
and apoptotic signaling. Most of the cell types present in the TME produce cytokines,
which can be broadly categorized into anti-tumor (IL-12, IFNγ, TRAIL), pro-tumorigenic
(IL-6, IL-23, IL-10, IL-17), and cytokines with direct roles on cancer cells (TGF-β, TNFα,
IL-6, FasL). An overview of a few cytokines that have been most extensively studied in
carcinogenesis will be provided below.
Transforming growth factor-beta (TGF-β), which normally plays an essential role
in development of the tissues of epithelial and neural origin, is also a major tumorpromoting

cytokine.

TGF-β

is

a most

prominent

regulator

of

angiogenesis,

immunosuppression, epithelial-to mesenchymal transition (EMT), ECM remodeling,
leading to tumor cell invasion and metastasis. The signaling events initiated by TGF-β
include activation of the Smad2/3, p38, JNK, ERK and Akt/mTOR pathways, all of which
contribute to tumorigenesis. Clinically, expression of TGF-β in the tumor correlates with
poor differentiation, advanced stage, metastases and poor survival (Lin and Zhao,
2015).
Interleukin-1 beta (IL-1β), a major regulator of the acute phase response, is
secreted in response to activation of the inflammasome pathway. IL-1β signaling results
in production of IL-1R, GM-CSF, G-CSF, TNFα, IL-6, IL-6, cortisol and nitric oxide, which
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is accompanied by fever, muscle and joint pain, fatigue, hypotension, neutrophilia and
thrombocytosis (Kasza, 2013). IL-1β plays a central role in cross talk between multiple
sell types in the TME. For example, it promotes tumor cell invasion by activation of
expression of several matrix metalloproteases (MMP-1,3,10 and 14). Furthermore, high
levels of IL-1β in serum or tumor tissue correlates with advanced tumor stage in multiple
tumor types (Whipple, 2015).
Interleukin 6 (IL-6), also known as “the truly pleiotropic cytokine” due to its
numerous roles in the immune system, such as promoting activation and proliferation of
T cells, differentiation of B cells, regulation of acute-phase response, as well as
hormonal-like ability to regulate vasculogenesis, lipid metabolism, insulin resistance and
neuropsychological processes (Hunter and Jones, 2015). The importance of IL-6 in
tumor progression via regulation of such essential signaling pathways as STAT3, NF-κB
and Wnt has been the subject of researchers’ interest for a while (Jarnicki et al., 2010),
yet the detailed mechanisms beyond these events are not always understood. A
substantial part of Chapters 2 and 3 of this thesis are dedicated to elucidating some of
these mechanisms.
Chemokines as a class were originally defined as cytokines which regulate
directional migration of immune cells. However, over time, it became clear that not only
can chemokines direct migration of non-immune cells, but that their function is not
limited to promoting chemotaxis. A good example is interleukin 8 (IL-8), also known as
the CXC chemokine ligand 8 (CXCL8), or “the first chemokine” (Baggiolini et al., 1989). It
is a classical chemoattractant for neutrophils, yet it can also activate downstream
signaling pathways like p38-MAPK or Erk-MAPK, and due to this outcome IL-8 is
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considered a pro-tumorigenic cytokine (Waugh and Wilson, 2008). Among other
chemokines

implicated

in

tumorigenesis

are

GROα/CXCL1,

GROβ/CXCL2,

GROγ/CXCL3, which affect cell proliferation and tumorigenicity in melanoma, ENA75/CXCL5, which regulates tumor growth, apoptosis and angiogenesis in melanoma,
and macrophage pro-inflammatory chemokine-3α (MIP-3α/CCL20), which promotes
tumor

cell

proliferation

in

pancreatic

cancer

(Coussens

and

Werb,

2002).

RANTES/CCL5, another chemokine with pro-tumorigenic properties (Aldinucci and
Colombatti, 2014), is a major focus of research described in Chapter 2 of this thesis.
The tumor microenvironment of esophageal squamous cell carcinoma
The pathogenesis of ESCC is tightly linked to chronic inflammation. In fact,
serum levels of acute phase response mediators C-reactive protein (CRP) and IL-6
correlate with the stage, depth of invasion and lymph node dissemination in ESCC
(Groblewska et al., 2012). Furthermore, positive IL-6 staining of the tumor sections has
been linked to distant metastases and poor treatment response in a study of 20 ESCC
patients (Chen et al., 2013). In agreement with these findings, a novel inflammationbased prognostic score (based on the CRP/Alb ratio) has been proposed to predict
overall survival in a retrospective study of 423 ESCC patients (Wei et al., 2015).
So far, only one study has attempted a more comprehensive analysis of the TME
in tumors of 55 ESCC patients (Liu et al., 2012). In addition to overall high proliferative
indices (based on Ki-67 staining), Dr. Liu and colleagues observed expansion of
myofibroblasts (interestingly, the density of these cells correlated with dissemination to
lymph nodes), increased microvessel density (quantified by CD34 staining), high levels
of pro-angiogenic factors VEGF and IL-8, as well as notable changes in the distribution
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of immune cells throughout the tumors. The majority of T cells (CD3+) and macrophages
(CD68+) were localized in the tumor stroma in the periphery and did not penetrate
efficiently into the tumor epithelium. These findings imply the existence of an
immunosuppressive milieu in these tumors.
CAFs in ESCC
One could argue that the cancer-associated fibroblasts represent the beststudied TME compartment in ESCC (Fig. 1), at the level of both clinical prognostic
associations and basic biology. For example, Dr. Ha and colleagues have assessed the
histopathological profile of CAFs in tissue samples from 116 ESCC patients and found
that the expansion of CAFs correlated with poor prognosis, increased microvessel
density and epithelial-to mesenchymal transition. Interestingly, expression patterns of
the CAF markers used in this study were quite heterogeneous, and only αSMA, FSP1,
and PDGFRα could serve as unfavorable prognostic factors for ESCC, while FAP and
PDGFRβ offered no significance (Ha et al., 2014).

Another study of 97 patients

investigated the association between expression of the most commonly used CAF
marker (αSMA) and clinico-pathological features of ESCC: positive αSMA staining in the
tumor stroma correlated with venous invasion, lymph node involvement, tumor
recurrence and predicted poor survival in patients with stage I and II ESCC (Saito et al.,
2014). Finally, a study of 95 patients who had undergone esophagectomy for ESCC
found that the abundance of CAFs in the original tumor correlated with a low 3-year
overall survival rate (Cheng et al., 2015).
A number of studies, including three publications from our lab, have identified
mechanisms that contribute to the tumor-promoting properties of CAFs in ESCC. For
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example, CAF-derived hepatocyte growth factor has been proved essential for invasive
properties of ESCC cells in 3D culture via activation of the Met receptor (Grugan et al.,
2010) (Fig. 1B). Direct contact with collagen I fibers (deposited by fibroblasts) stimulates
production of the lysosomal enzyme cathepsin B in tumor cells, which, in addition to
directly modifying the ECM, also leads to enhanced secretion of TGFβ1 (Andl et al.,
2010) (Fig. 1A,B). Another mechanism by which CAFs promote invasion of ESCC cells
into the ECM is by promoting expression of the matricellular protein periostin (in an
EGFR- and mutant p53-dependent matter), which can only be detected in the invading
tumor cells in vitro and in ESCC patient samples (Michaylira et al., 2010). The work
described in Chapter 2 of this thesis is aimed to deepen our understanding of the ways
in which the CAFs promote ESCC progression.
Immune microenvironment in ESCC
Since chronic inflammation plays such a major role in ESCC biology, many
groups have focused their studies on the role of immune cells components in this
disease. Existing evidence of the role of several such populations (MDSC, Treg, Th17
and TAM) will be summarized in this section (Fig. 2).
The myeloid-derived suppressor cells (MDSCs) are a heterogeneous population
of immature myelocytes with one shared property: their ability to suppress activation of
both innate and antigen-specific immune response. Chapter 3 of this thesis is dedicated
to investigating the detailed mechanisms driving expansion of and acquisition of
immunosuppressive capacity by MDSCs in a murine model of ESCC (Karakasheva et
al., 2015). In addition to this work, another publication reports on the role of MDSCs in a
chemical carcinogenesis-induced model of ESCC, and these data are accompanied by a
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survey of an MDSC-like cell population in peripheral blood of ESCC patients, where the
presence of these cells was associated with advanced disease, poor prognosis and
resistance to therapy (Chen et al., 2014).
The involvement of tumor-associated macrophages (TAMs) has been well
appreciated in many types of cancer, but in ESCC this cell subset has not been
extensively studied. There are, however, some promising data: secretion of MCP-1 by
ESCC cells results in TAM infiltration and production of pro-angiogenic factors, while the
presence of TAMs is also associated with poor response to therapy and poor prognosis
in ESCC (Shigeoka et al., 2013). Two subsets of T cells – Treg and Th17 – also
contribute to formation of an immunosuppressive microenvironment in ESCC (Fig. 2).
Tumor cell-derived chemokines CCL17 and CCL22 appear to be responsible for
recruitment and expansion of Tregs in this disease. The presence of Tregs also has
prognostic significance. Treg infiltration is associated with ESCC invasion, metastases,
disease severity and survival post-chemotherapy. Furthermore, in patients receiving
neoadjuvant chemoradiotherapy, retention of Tregs in the tumor is associated with poor
treatment response and survival (Lin et al., 2016). Some reports demonstrate the
relevance of the Th17 subset of T helper cells in ESCC: increased presence of these
cells is detected in both peripheral blood and tumor tissue, and the degree of expansion
correlates with disease stage (Lin et al., 2016). It is important to keep in mind, however,
that the role of Th17 cells in cancer is still a subject to debate and more studies are
needed to clarify this issue.
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Pro-inflammatory signaling in ESCC
The signal transducer and activator of transcription 3 (STAT3) is among the
most-investigated signaling pathways that regulate inflammation in cancer, and ESCC is
not an exception: several studies, as well as our own work described in Chapter 2, have
reported elevated levels activated STAT3, as well as its major inducer IL-6 and IL-6Rα
(Leu et al., 2003; Yan et al., 2008). Furthermore, STAT3 activation correlates with poor
prognosis in ESCC patients who have undergone esophagectomy for ESCC (Li et al.,
2014). Mechanistically, in vitro studies demonstrated that STAT3 signaling promotes
production of anti-apoptotic factors (Leu et al., 2003), while small molecule inhibitor
static restores radiosensitivity to ESCC cells in vivo (Zhang et al., 2014a).
The nuclear factor kappa B (NF-κB) pathway is another example of a cancer cell
hijacking a normal immune signaling pathway to induce an aberrant state of chronic
inflammation. Our lab has previously reported overexpression of the p65 subunit of NFκB in a genetic model of ESCC (Stairs et al., 2011). Overexpression of NF-κB have also
been associated with poor prognosis in patients with ESCC (Hatata et al., 2012). IL-8,
one of the major upstream regulators of NF-κB signaling, is also associated with disease
progression, inflammation, metastases and poor prognosis in ESCC patients (Ogura et
al., 2013). Interestingly, CCL5 (also known as RANTES), which is one of the main
players in the mechanism described in Chapter 2, is a downstream target of the NF-κB
pathway (Aldinucci and Colombatti, 2014).
It is important to note the existence of a complex interdependent cross-talk
between the STAT3 and NF-κB signaling (Jarnicki et al., 2010).

One of the most

prominent downstream targets shared by the two pathways is the gene encoding
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cyclooxygenase-2 (COX-2). Interestingly, a positive correlation exists between COX-2
expression and the degree of dysplasia in esophageal tissue (Zhi et al., 2006), while
intense COX-2 staining is associated with poor prognosis and resistance to
chemotherapy in patients with ESCC (Akutsu et al., 2011). Mechanistically, COX-2
inhibition leads to decreased proliferation of and lower prostaglandin E2 production by
ESCC cells in vitro, as well as to decreased tumor progression in vivo (Zhi et al., 2006).
Finally, the programmed cell death protein-1 (PD-1) pathway, an increasingly
popular target for cancer therapy, has also proven to be important in esophageal
carcinogenesis (Fig. 2). Indeed, elevated expression of the pathway ligands PD-L1 and
PD-L2 in cancer cells correlates with decreased survival in ESCC patients, while
increased PD-L1 expression is associated with greater depth of tumor invasion and poor
survival (Lin et al., 2016).
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Figures and figure legends
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Figure 1

Figure 1-1: Stromal compartment of the esophageal TME. (a) Neoplastic cells
secrete growth factors to activate quiescent fibroblasts designated as CAFs. CAFs can
proliferate to contribute to desmoplasia, secreting ECM components such as fibronectin
(FN) to enhance the development of the primary tumor niche. CAFs also secrete
cytokines that promote tumor cell survival (anti-apoptosis). (b) Later in tumorigenesis,
CAFs remodel the ECM with enzymes like lysyl oxidase (LOX) and MMPs as well as
ECM components like dermatan sulfate (DS) and hyaluronan (HA) to promote invasion.
CAFs also secrete growth factors that trigger tumor cells to undergo EMT and
chemokines that induce tumor cell migration. CAFs can also promote angiogenesis via
VEGF secretion. (Modified from Lin E., Karakasheva T., et al., Oncogene 2016).
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Figure 2

Figure 1-2: Immune landscape in esophageal cancer. Several immune cell types
disrupt antitumor immunity (cytotoxic CD8+ T cells) in the TME. Tregs exert
immunosuppressive function via direct contact with effector T cells or by molecules such
as adenosine or immunosuppressive cytokines (IL-10 and IL-35). Th17 release
adenosine by ectoenzymatic (CD39, CD73) function and have the ability to convert into
Tregs (dashed line). MDSCs directly inhibit T-cell activation and NK cell cytotoxicity,
while also inducing Tregs. TAMs and tumor cells both express PD-L1/2 to inhibit T-cell
activation via the PD-1 receptor. Altogether, these cells suppress antitumor immunity
while also promoting tumor growth and progression by various mechanisms. (Modified
from Lin E., Karakasheva T., et al., Oncogene 2016).
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Chapter 2 CHAPTER 2: The impact of interaction between tumor cells and cancerassociated fibroblasts in esophageal squamous cell carcinoma
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Abstract
Esophageal cancer is a leading cause of cancer-related death worldwide. The
prognosis for these patients remains poor, and targeted therapies are largely absent.
Chronic inflammation and the reactive stroma are among the driving forces for
esophageal cancer initiation, progression and dissemination. We have identified the
cytokines IL-6 and RANTES as prominent mediators of this cross-talk in esophageal
carcinogenesis. Loss of IL-6 or RANTES potently suppresses tumorigenesis in 3D
models (organotypic and organoid) of esophageal cancer, as well as in subcutaneous
xenograft transplant tumors. Furthermore, we found that inhibiting IL-6 or RANTES
signaling (with tocilizumab, a neutralizing antibody to IL-6 receptor (IL-6R), or maraviroc,
a small molecule CCR5 inhibitor, respectively), suppresses tumor growth in vivo via
inhibition of STAT3 and ERK1/2 signaling pathways. We also demonstrate that cotreatment with tocilizumab and maraviroc is more effective than either agent alone in
vitro in 3D organotypic culture model of ESCC, providing a rationale for testing
combination therapy in vivo. We propose inhibition of IL-6 and RANTES signaling as a
novel approach to treatment of esophageal cancer, as well as potentially other types of
cancer, particularly squamous cell carcinomas.
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Introduction
Esophageal cancer is the 8th most common cancer type and the 6th leading
cause of cancer-related death worldwide (Napier et al., 2014). The 5-year survival rate
for esophageal cancer patients is estimated to be 15-20%; furthermore, rather than
declining, the incidence of esophageal cancer is expected to increase by 140% in the
next 10 years (Napier et al., 2014). There are two subtypes of esophageal cancer –
esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC),
which are characterized by distinct histology, location and pathogenesis. ESCC
represents up to 90% of all esophageal cases worldwide, but EAC is the prevalent type
in the United States and Europe (Rustgi and El-Serag, 2014). The poor prognosis and
increasing incidence and mortality indicate a need for improved understanding of
mechanisms underlying esophageal cancer initiation and progression. Investigating the
interaction between the tumor cells and surrounding microenvironment presents an
opportunity to address some of these issues in a thoughtful and targeted way.
Cancer-associated fibroblasts (CAFs) are among the most prominent cell types
in the tumor microenvironment. CAFs have been reported to predict outcome (Ha et al.,
2014; Saito et al., 2014) and promote tumorigenesis (Zhang et al., 2009) in esophageal
cancer. Previous reports from our lab have demonstrated that CAFs mediate ESCC cell
invasion via secretion of hepatocellular growth factor (HGF) (Grugan et al., 2010) or
cathepsin B (Andl et al., 2010). Furthermore, certain ECM components, secreted by
CAFs, such as periostin, dermatan sulfate and fibronectin, are implicated in ESCC
progression (Michaylira et al., 2010; Thelin et al., 2012; Wong et al., 2013; Zhang et al.,
2005). It is therefore believed that therapeutically disrupting the cross-talk between
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CAFs and tumor cells would be beneficial not only in esophageal cancer, but other types
of cancer as well.
Interleukin 6: a cytokine involved in the tumor microenvironment
Interleukin 6 (IL-6) is a pleiotropic cytokine, widely appreciated as a major
regulator of the acute phase response, yet having numerous functions within the
immune system, lipid metabolism, insulin resistance, mitochondrial function and the
neuroendocrine system (Hunter and Jones, 2015). IL-6 signaling is mediated by a
heterodimeric receptor complex comprised of the ligand-binding subunit (IL-6Rα, or
CD126; (Yamasaki et al., 1988)) and the signal-transducing subunit (gp130, or CD130;
(Hibi et al., 1990)). The best appreciated signaling event induced by IL-6 is the signal
transducer and activator of transcription 3 (STAT3) pathway, which has well
characterized functions in promoting tumor progression (Guo et al., 2012). However,
recent studies have demonstrated that IL-6 can activate additional signaling pathways,
including MEK/ERK and PI3K/AKT (Costa-Pereira, 2014; Guo et al., 2012).
Increased secretion of IL-6 has been detected in multiple epithelial cancers,
including, but not limited to, head and neck squamous cell carcinoma (HNSCC), lung
cancer, colorectal cancer, gastric cancer, breast cancer, ovarian carcinoma, and other
cancers (Guo et al., 2012). In colorectal cancer patients, expression of IL-6 is associated
with tumor stage, survival and metastasis, while colorectal cancer cell lines respond to
IL-6 with stimulated growth in vitro (Waldner et al., 2012). In a chemical carcinogeninduced model of gastric adenocarcinoma loss of IL-6 was associated with a dramatic
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decrease in tumor incidence and reduced tumor number and size, as well as decreased
levels of activated STAT3 (Kinoshita et al., 2013).
In ESCC, IL-6 is known to suppress apoptosis (Leu et al., 2003) and cisplatininduced cytotoxicity (Suchi et al., 2011) in vitro. Furthermore, inhibition of STAT3
promotes radiosensitivity in a subcutaneous xenograft ESCC model in vivo, while in
ESCC patients positive IL-6 staining in the tumor is associated with poor prognosis
(Chen et al., 2013). Serum levels of IL-6 in esophageal cancer patients correlate with
tumor stage, depth of tumor invasion and dissemination to lymph nodes (Groblewska et
al., 2012), while presence of soluble IL-6R in the serum is a predictor of poor response
to neoadjuvant therapy in patients with ESCC (Makuuchi et al., 2013). In ESCC, IL-6 has
been reported to activate STAT3, ERK1/2 and PI3K signaling in vitro, yet the latter
pathway was not essential for the antiapoptotic activity of IL-6 (Leu et al., 2003).
Reagents for therapeutic targeting of IL-6 signaling were initially developed for
autoimmune diseases. Siltuximab, an IL-6 neutralizing antibody has been approved by
the FDA for treatment of Castleman’s disease (Deisseroth et al., 2015), while
tocilizumab, an antibody to IL-6Rα, has been approved by the FDA for treatment of
rheumatoid arthritis (Thompson, 2010). Encouraged by favorable preclinical data
(Goumas et al., 2015), a number of clinical studies was initiated to investigate the use of
siltuximab in cancer, yet, while the therapy was generally well tolerated, no clinical
efficacy was detected (Angevin et al., 2014; Rossi et al., 2015). These results have been
attributed, in part, to the ability of tumor cells to increase IL-6 production, thus trapping
the neutralizing antibody in circulation and preventing its access to the tumor (Hunter
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and Jones, 2015). By contrast, neutralization of the IL-6 receptor has the potential to
overcome this barrier.
Treatment with tocilizumab resulted in suppressed tumor growth rate,
accompanied by reduced STAT3 phosphorylation, in a murine model of oral cancer, the
predominant subtype of HNSCC (Shinriki et al., 2009). Furthermore, tocilizumab has
been proven to be effective in pre-clinical studies of breast cancer, where its
administration resulted not only in stalled tumor growth, but also reduced lung
metastases and depletion of CD11b+Gr-1+ myeloid-derived suppressor cells (Chang et
al., 2013). A large number of clinical trials for the use of tocilizumab in cancer are
ongoing (Table 1), and several novel agents are currently in pre-clinical development
(Hunter and Jones, 2015).
RANTES: a chemokine involved in the tumor microenvironment
RANTES (regulated on activation, normal T-cell expressed and secreted), also
known as CCL5, is a chemokine from the C-C chemokine ligand family. It is produced by
activated T cells (but not B cells), platelets, monocytes, synovial fibroblasts and certain
types of epithelia (Appay and Rowland-Jones, 2001). Production of RANTES is induced
by NF-κB and JNK signaling (Chenoweth et al., 2012). Additionally, acetylated Snail, as
well as AP-1 are viewed as transcriptional activators of RANTES, while CREB may be its
transcriptional repressor (Hsu et al., 2014; Lv et al., 2013). In addition, adipocytes in the
microenvironment and cellular ER stress may stimulate secretion of RANTES
(D’Esposito et al., 2016; Zhang et al., 2014b) .
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RANTES is a potent chemoattractant for eosinophils, monocytes, T cells and
basophils (Kameyoshi et al., 1992; Kuna et al., 1992). However, it has other functions,
such as promotion of proliferation, invasion and angiogenesis (Aldinucci and Colombatti,
2014). RANTES acts through a number of G-protein-coupled receptors (GPCRs): CCR1
(Neote et al., 1993), CCR3 (Ben-Baruch et al., 1995), CCR5 (Raport et al., 1996) and
auxiliary receptors CCR4 (Udi et al., 2013) and CD44 (Roscic-Mrkic et al., 2003).
Interestingly, these receptors can be activated by other chemokines, such as MIP-1α
(CCR1), eotaxin (CCR3) and MIP-1β (CCR5). Among these GPCRs, CCR5 is by far the
best-studied, due to its function as a co-entry receptor for the human immunodeficiency
virus (HIV) (Deng et al., 1997).
RANTES expression has been associated with several types of cancers. For
example, its levels are elevated in both plasma and tumor tissue of patients with breast
and cervical cancers (Niwa et al., 2001). Furthermore, patients with gastric
adenocarcinoma have significantly higher levels of RANTES in serum, which are
associated with reduced histological differentiation, greater degree of tumor invasion,
advanced tumor stage and reduced overall survival (Sima et al., 2014).
Certain functions of RANTES in cancer are related to its activity in the
immunosuppressive cell populations.
alternative

differentiation

and

For example, it contributes to recruitment,

immunosuppressive

capacity

of

myeloid-derived

suppressor cells in a murine model of triple-negative breast cancer, as well as in an ex
vivo differentiation assay of human patient-derived CD33+ suppressor cells (Zhang et al.,
2013). The binding of RANTES to CCR5 leads to phosphorylation of the p38 MAP
kinase, while activation of JAK2/3 and subsequent phosphorylation of STAT1/3 (Wong et
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al., 2001). Furthermore, RANTES-CCR5 signaling drives homing of regulatory T cells to
the tumor and enhances their suppressive capacity in murine models of pancreatic and
colorectal cancers (Chang et al., 2012; Tan et al., 2009).
RANTES is essential in mediating the cross-talk between tumor cells and
surrounding stromal cells. Treatment of human ovarian cancer cells with cisplatin
induces secretion of RANTES by CAFs, which activates the STAT3 and PI3K/AKT
signaling pathways in tumor cells, thereby leading to resistance to cisplatin (Zhou et al.,
2016). Furthermore, RANTES (along with IL-6) promotes mesenchymal stem cellinduced migration of human breast cancer cells in vitro (Gallo et al., 2012).
Tumor cell-autonomous functions of RANTES have been reported. RANTESCCR5-induced STAT3 signaling promotes tamoxifen resistance in human breast cancer
cells in vitro (Yi et al., 2013). In human lung cancer cells, CCR5 ligation by RANTES
promotes migration via activation of the PI3K/AKT and NF-κB signaling pathways
(Huang et al., 2009).
Historically, investigation of the pro-tumorigenic functions of RANTES has been
focused on its ability to activate CCR5, yet, it is becoming apparent that other GPCRs
are quite important as well. Importantly, pharmacological inhibition of CCR5 with TAK779, while able to suppress the growth of primary tumors, failed to prevent peritoneal
dissemination of colorectal cancer cells in vivo, compared to treatment with a RANTESneutralizing antibody (Cambien et al., 2011). Accordingly, RANTES-CCR1 interaction
has been reported to promote invasion of taxane-resistant prostate cancer cells via
ERK1/2 and Rac signaling (Kato et al., 2013), while NF-κB signaling induced by
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autocrine activation of CCR1 and CCR3 by RANTES drives metastatic dissemination of
ovarian cancer cells (Long et al., 2012).
There have been a number of studies to evaluate inhibition of RANTES as an
approach to cancer therapy. Several small molecule inhibitors have been developed to
target CCR5: maraviroc (Wood and Armour, 2005), vicriviroc (Strizki et al., 2005), TAK779 (Baba et al., 1999) and anibamine (Zhang et al., 2012). Maraviroc has been
approved by the FDA and successfully used for HIV therapy (Van Der Ryst, 2015),
resulting in its potential application to target RANTES in cancer. For example, treatment
with maraviroc prevents development of tumors in a murine model of hepatocellular
carcinoma (Ochoa-Callejero et al., 2013), inhibits growth of orthotopically transplanted
colon cancer cells (Tanabe et al., 2016), reduces the capacity of gastric cancer cells to
disseminate (Mencarelli et al., 2013) and prevents metastasis of basal breast cancer
cells in vivo (Velasco-Velázquez et al., 2012). Finally, a pilot clinical study has been
published where maraviroc was used in 11 patients with advanced refractory colorectal
cancer. This resulted in central tumor necrosis and a partial remission of lung
metastases. A subgroup of patients received maraviroc in combination with
chemotherapy, leading to a partial response in 3/5 (60%) cases (Halama et al., 2016).
Other GPCRs may significantly contribute to the pro-tumorigenic effects of
RANTES (Cambien et al., 2011). Therefore, the capture of the ligand with a neutralizing
antibody or a combination of multiple small molecule inhibitors may be beneficial. A
selective CCR1 inhibitor J113863 (Pevida et al., 2014) and its trans-isomer UCB35625
(Sabroe et al., 2000) have been developed and tested in vivo, but no reports of their
utility as clinical therapeutic agents are available thus far. In addition to maraviroc,
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mogamulizumab, a neutralizing antibody to human CCR4, is being actively studied in the
clinic as a novel agent for therapy of hematologic malignancies (Table 1) since CCR4 is
one of the receptors utilized by RANTES, mogamulizumab could be tested in solid
malignancies as well.
Of importance to our study, there is evidence for cooperation between IL-6 and
RANTES in several contexts, including cancer. For instance, RANTES/CCR5 signaling
promotes IL-6 secretion by human synovial fibroblasts via the PKCδ/c-Src/c-Jun and AP1 signaling pathways in a model of osteoarthritis (Tang et al., 2010). In combination with
IL-6, RANTES can stimulate proliferation of prostate cancer cells in vitro via ERK1/2
signaling (Colombatti et al., 2009). Furthermore, potent tumor-promoting signaling
circuits converging on RANTES and IL-6 in murine models of KRAS-driven lung cancer
(Zhu et al., 2014) and IKBKE-driven triple-negative breast cancer (Barbie et al., 2014)
have been reported. Interestingly, there may be ways to therapeutically suppress the
production of pro-tumorigenic cytokines: zoledronic acid can impair the secretion of
RANTES and IL-6 in mesenchymal stem cells, thus blocking their interaction with breast
cancer cells (Gallo et al., 2012).
In this study, we use 3D culture approaches and murine xenotransplant models
to demonstrate a role for tumor cell-derived IL-6 and RANTES in mediating the
interaction between tumor cells and CAFs in esophageal squamous cell carcinoma. We
define STAT3 and ERK1/2 signaling pathways as the likely predominant downstream
mediators of the two cytokines in ESCC. Furthermore, we confirm that IL-6 and RANTES
are novel and promising targets for ESCC therapy that can be targeted by tocilizumab (a
neutralizing antibody to human IL-6Rα), maraviroc (small molecule CCR5 antagonist), or
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a combination of both. Given the existing evidence of involvement of IL-6 and RANTES
in breast, lungs and gastric cancer progression, we propose that this treatment strategy
can be expanded to other cancer types.
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Results
Interaction between tumor cells and CAFs induces changes in cell biology
Desmoplasia is one of the key characteristics of ESCC (Lin et al., 2016), which
prompted us to investigate the consequences of interaction between the tumor cells and
CAFs. First, we have evaluated the changes in gene expression profiles in TE11 cells
grown in mono-culture, compared to co-culture with the FEF3303 esophageal
fibroblasts. Upon magnetic bead-based purification from co-culture, RNA was extracted
from the tumor cells, followed by qPCR analysis. We have found significant changes in
expression of multiple genes encoding matricellular proteins (FBN1, POSTN, SPARC,
THBS1), growth factors and their receptors (EGF, HGF, VEGFA, VEGFB, VEGFC, MET,
PTK2, FLT1, KDR), EMT-related genes (CDH2, SNAIL2), cytokines, chemokines and
their receptors (IL-6, CXCL1, CXCL5, IL-6R, CCR1, CCR4), as well as components of
inflammatory signaling pathways (STAT3, SOCS3, SOCS2) (Fig. 1A).
We next decided to investigate the effect of co-culture on cell proliferation.
Measured by flow cytometry (dilution of the CFDA-SE dye), three out of four ESCC cells
lines (TE1, TE6, HCE7) had increased proliferation rates when co-cultured with
fibroblasts (Fig. 1B). Furthermore, proliferation of either FEF3 or FEF3303 esophageal
fibroblasts was significantly enhanced by any of the ESCC cells tested (Fig. 1B).
In a 3D organotypic culture model system, addition of FEF3303 esophageal
fibroblasts to the epithelial layer (TE11) resulted in a dramatic increase in epithelial layer
thickness, as well as enhanced invasion into the extracellular matrix (Fig. 1C, 1D).
Importantly, co-injection of TE11 cells with FEF3303 or ESCC-Fb-1 fibroblasts
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subcutaneously into flanks of nude mice significantly promoted tumor growth rate, when
compared to TE11 cells alone (Fig. 1E). These findings underscore the importance of
activated fibroblasts in ESCC initiation and progression.
IL-6 and RANTES are potential mediators of cross-talk between tumor cells and
CAFs in ESCC
To identify potential mediators of cross-talk between epithelial tumor cells and
CAFs in esophageal cancer, we have conducted a cytokine array analysis of conditioned
media from co-cultures of ESCC cells with esophageal CAFs. We have identified six
cytokines (IL-6, RANTES, ENA-78, GRO-α, IL-8 and MCP3) with enhanced secretion in
co-culture, compared to either cell line in mono-culture (Fig. 2A). Secretion of IL-6 was
the most dramatically and specifically increased in co-culture, while RANTES was the
second most-upregulated in co-culture. We have confirmed the cytokine array results for
IL-6 and RANTES by ELISA and observed pronounced upregulation of both cytokines in
co-culture of TE11 ESCC cells and FEF3303 fibroblasts (Fig. 2B).
We have immuno-stained sections of paraffin-embedded samples of human
ESCC or normal esophagus for IL-6 and RANTES. Interestingly, we have observed
increased staining for IL-6 and RANTES in both fibroblasts and epithelial cells in ESCC
(Fig. 3A, B). Specifically, in the normal esophagus IL-6 is expressed at low levels in the
fibroblasts, as well as the smooth musculature (muscularis mucosae), and is absent in
the epithelial layer. By contrast, in ESCC high expression of IL-6 is found in fibroblasts
and epithelial cells. RANTES is expressed at low levels in the normal esophageal
epithelium and absent in normal stroma, while in ESCC RANTES expression in the
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epithelium is intense, and a certain amount is detected in the fibroblasts. These data
suggest that IL-6 and RANTES may be relevant to ESCC pathogenesis.
Tumor cell-derived IL-6 promotes tumorigenic properties of ESCC
To investigate the role of epithelial cell-derived IL-6 in esophageal cancer, we
have used the CRISPR/Cas9 method to knock out IL-6 in TE11 cells, TE11 IL-6KO1 and
IL-6KO2 (Fig. 4). We have observed significant differences in two types of 3D culture
and in vivo. The 3D organotypic cultures formed by TE11 IL-6KO cells reveal decreased
epithelial layer thickness and reduced invasion (Fig. 5A). Furthermore, we found that
TE11 IL-6KO cells formed smaller 3D organoids with “normalized” morphology,
compared to IL-6WT cells (Fig. 5B). Subcutaneous xenograft tumors formed by the
TE11 IL-6KO cells are characterized by stalled growth rates (Fig. 5C).
Targeting IL-6 signaling as a therapeutic approach in ESCC
Since we found that IL-6 signaling drives ESCC progression, we conducted a
therapeutic study using tocilizumab, a neutralizing antibody against the human IL-6Rα.
Nude mice bearing subcutaneous xenograft tumors formed by TE11 and FEF3303 cells
were treated with tocilizumab or a human IgG isotype control. Interestingly, tocilizumab
treatment resulted in stalled tumor growth (Fig. 6A), which was accompanied by
reduced STAT3 and ERK1/2 signaling (Fig. 6B).
Tumor cell-derived RANTES promotes tumorigenic properties of ESCC
We have next generated single cell-derived subclones of TE11 cells with
CRISPR/Cas9-mediated knockout of RANTES: TE11 RantesKO1 and RantesKO2 (Fig.
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4). In the 3D organotypic cultures formed by TE11 RantesKO cells there were fewer
nucleated epithelial layers with reduced invasion (Fig. 7A). In addition, we found that
RANTES-deficient 3D organoids were smaller and had “normalized” morphology (Fig.
7B). Finally, subcutaneous xenograft tumors formed by the TE11 RantesKO cells had
decreased growth rates, compared to RantesWT tumors (Fig. 7C).
Targeting RANTES signaling as a therapeutic approach in ESCC
To target RANTES signaling in vivo, we selected maraviroc, a small-molecule
antagonist of CCR5. We found that treatment with maraviroc suppressed growth of
subcutaneous xenograft tumors formed by TE11 and FEF3303 cell lines co-implanted
into hind flanks of nude mice (Fig. 8A), compared to treatment with the vehicle (DMSO).
Surprisingly, tumors from the maraviroc-treated animals had significantly reduced
ERK1/2 signaling in both epithelial cells and fibroblasts, which was accompanied by a
trend of reduced STAT3 signaling (Fig. 8B).

Co-targeting of IL-6 and RANTES is a preferential strategy to ESCC therapy in
vitro
Our results indicate that IL-6 and RANTES play an important role in ESCC
pathogenesis and that at least part of their functions are mediated through the STAT3
and ERK1/2 signaling pathways (Fig. 6,8). This led us to investigate whether
simultaneous inhibition of IL-6 and RANTES signaling may provide a further therapeutic
benefit. To that end, we treated 3D organotypic ESCC cultures with tocilizumab,
maraviroc or a combination of both. Interestingly, we have found that though either drug
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alone or in combination suppressed tumor cell invasion, only the combination of
tocilizumab and maraviroc produced a significant reduction in the number of nucleated
epithelial layers (Fig. 9). These data indicate that simultaneous inhibition of both IL-6
and RANTES-induced signaling may indeed be a better approach for the treatment
ESCC, although in vivo testing of this hypothesis is needed.
STAT3 and ERK1/2 signaling promotes ESCC tumorigenesis
We have next treated 3D organotypic cultures of ESCC with small molecule
inhibitors of STAT3 and MEK/ERK signaling pathways (stattic and trametinib,
respectively). Surprisingly, while treatment with either drug individually suppressed
tumor cell invasion, the combination of stattic and trametinib inhibited invasion even
more efficiently than either drug alone (Fig. 10A,B). Only STAT3 inhibition led to
reduced number of nucleated cells in the epithelial layer, while only MEK/ERK inhibition
efficiently suppressed cell proliferation, measured by Ki-67 staining (Fig. 10A,B).
Interestingly, only combination of stattic and trametinib promoted apoptosis, while monotherapy with either drug induced no change, measured by immune-staining for cleaved
caspase 3 (Fig.10A,B). These data suggest that the signaling pathways induced by IL-6
and RANTES promote tumor cell invasion, proliferation and evasion of apoptosis in
ESCC.
IL-6 signaling as a therapeutic target in multiple types of cancer
To determine the potential of targeting IL-6 signaling in other cancers besides
esophageal, we performed in silico survival analysis using IL-6 and IL-6R expression
(RNAseq) data acquired from TCGA. Remarkably, we found that low relative expression
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of IL-6 and IL-6R was correlated with improved survival, not only in esophageal cancer
but in the TCGA pan-cancer dataset (Fig. 11A). In addition, immunohistochemical
staining for IL-6 in head and neck squamous cell carcinoma (HNSCC) and gastric
adenocarcinoma showed overexpression in tumor sections compared to matched
normal oral and gastric mucosa, respectively (Fig. 11B,C). (All data in this section are
used with permission from Eric Lin).
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Discussion
The importance of the tumor microenvironment in cancer in general, and in
esophageal cancer specifically, is well appreciated (Lin et al., 2016). Yet, the precise
mechanisms of interaction between different components of the TME and the tumor cells
remain to be elucidated. We focused our attention on fibroblasts, because of existing
evidence linking CAFs to prognosis and therapeutic outcome in ESCC (Ha et al., 2014;
Saito et al., 2014). Specifically, we wanted to identify novel mediators of interaction
between CAFs and esophageal tumor cells.
Based on the cytokine array results, IL-6 and RANTES were selected as likely
candidates, since they were specifically upregulated in co-cultures of ESCC and
esophageal CAFs, compared to mono-cultures (Fig. 2). This was strengthened by the
IHC staining of human ESCC biopsies, where either IL-6 or RANTES staining was
significantly stronger in both epithelial cells and fibroblasts, compared to normal
samples. Previous studies have demonstrated the role of ESCC cell-derived IL-6 in
evasion of apoptosis (Leu et al., 2003), and our findings support this premise.
Importantly, we show herein that expression of IL-6 by tumor cells is induced through
interaction with CAFs. Yet, our data from 3D organoid cultures suggest an autocrine IL-6
signaling mechanism (Fig. 5B), in addition to paracrine signaling induced by fibroblastderived IL-6. To our knowledge, no reports describing the function of RANTES in ESCC
have been published. Our observations regarding the role of RANTES in the growth and
invasiveness of 3D tumor cultures (Fig. 7), are noteworthy and in agreement with current
perspectives on the importance of RANTES in other cancers (Aldinucci and Colombatti,
2014).
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Tocilizumab is widely used in clinic to inhibit IL-6 signaling in autoimmune
diseases, and a number of pre-clinical studies have indicated its efficacy in cancer.
Since our data demonstrate that IL-6 promotes esophageal carcinogenesis, we have
tested tocilizumab in a xenograft model of ESCC and observed a potent tumorsuppressive effect, which was accompanied by decreased STAT3 and ERK1/2 signaling
in both epithelial and fibroblast compartments (Fig. 6). Furthermore, we provide
evidence of IL-6 involvement in pathogenesis of multiple types of cancer, such as head
and neck squamous cell carcinoma and gastric adenocarcinoma (Fig. 11). Similarly,
prompted by our finding that RANTES is also important for ESCC progression, we
sought to pharmacologically inhibit its signaling (at least partially) in vivo. In our
xenograft model, maraviroc suppressed ESCC tumor growth, likely via inhibition of
STAT3 and ERK1/2 signaling pathways (Fig. 8).
Importantly, we demonstrate that co-inhibition of signaling induced by IL-6 and
RANTES provides a better tumor-suppressive effect than inhibition of either cytokine
alone in vitro (Fig. 9). Interestingly, a synergistic interaction between IL-6 and RANTES
has been previously described in aggressive subtypes of lung and breast cancer (Barbie
et al., 2014; Zhu et al., 2014). Along with our data, this suggests that co-targeting IL-6
and RANTES could provide for a superior treatment strategy not only in ESCC, but in
other types of cancer.
In agreement with previous publications (Aldinucci and Colombatti, 2014; Leu et
al., 2003), we find that the pro-tumorigenic role of IL-6 and RANTES in ESCC is
mediated via STAT3 and ERK1/2 signaling pathways. In addition to suppression of
apoptosis, we also found that these pathways mediate tumor cell proliferation and
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invasion (Fig. 10). These findings provide a rationale for potential future studies of
combining downstream inhibitors of these pathways for therapeutic application, which
could provide a better outcome, compared to “upstream intervention”, such as receptor
blockade with tocilizumab and/or maraviroc.
Since the key role of activated stroma in the establishment and progression of
cancer in general, and ESCC in particular, is no longer under question, the next logical
step should be to use this knowledge in designing the new generation of cancer
therapeutics. In addition to promoting tumorigenesis, CAFs are known to contribute to
resistance to multiple treatments, including neoadjuvant chemotherapy, anti-angiogenic
therapy, and receptor tyrosine kinase inhibitors (Pietras and Östman, 2010). We have
identified two cytokines that mediate the interaction between tumor cells and CAFs in the
esophageal cancer microenvironment, as well as the key signaling pathways utilized by
these cytokines. These data shall be used to develop novel targeted approaches to
cancer therapy, as well as to improve the currently used strategies. For example,
combining inhibition of IL-6 and RANTES with chemo- or radiotherapy may produce
superior results.
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Materials and methods

Cell lines and reagents
The TE and HCE cell lines were cultured in DMEM supplemented with
10% FBS (Sigma) and 1x penicillin/streptomycin (Invitrogen) in 5% CO 2 as
described previously (Okano et al., 2000). FEF3 and FEF3303 cell lines were
cultured

in

DMEM

supplemented

with

15%

FBS

(HyClone)

and

1x

penicillin/streptomycin in 5% CO2 as described previously (Okawa et al., 2007).
The ESCC-Fb-1 and ESCC-CAF-J1 cell lines have been generated from
esophageal biopsies. The tissues were incubated in dispase/collagenase/Y27632
solution for 45 min at 37oC (vortexed every 10 minutes and mechanically
disrupted with a P1000 pipette tip). Preparations were incubated for 10 minutes
at 37oC in 0.25% trypsin/EDTA. Soybean trypsin inhibitor (Sigma) was used to
inactivate trypsin. The resulting cell suspension and tissue fragments were forced
through a 70 μm strainer, centrifuged, resuspended in fibroblast media
supplemented with fungizone (Gibco) and gentamicin (Gibco) and seeded into
one well of a 6-well plate. Culture media was replaced every 48 hours or as
needed.
Stattic, trametinib and Maraviroc were purchased from Selleckchem, and
tocilizumab - from the pharmacy of the Hospital of the University of Pennsylvania.
Human IgG control was from Sigma.
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3D organoid and organotypic culture
The cells were trypsinized, mixed with matrigel (BD) and seeded at 3000
cells/well. After matrices solidified, growth media were added (CnT Prime 3D
Barrier Media for Epidermal Models, ZenBio) and replaced every 48-72 hours.
For IHC, organoids were recovered on day 12 from matrigel with dispase
digestion, fixed overnight in 4% paraformaldehyde and embedded in 2% BactoAgar:2.5% gelatin before dehydration and embedding in paraffin.
TE11 cells were grown in organotypic culture as described previously
(Kalabis et al., 2012), with the following modifications. Transwell inserts (30mm,
PET, 0.4μm pore; Millipore) were used to support the 3D collagen/matrigel
matrices, containing 27% Nutragen bovine collagen solution type I (Advanced
Biomatricx), 18% matrigel (BD), 1× minimal essential medium with Earle’s salts
(BioWhittaker), 1.68 mM L-glutamine (Cell- gro), 10% fetal bovine serum
(Hyclone), 0.15% sodium bicarbonate (BioWhittaker), and 2×10 4 FEF3303
fibroblasts. On day 7 of culture, 2.5x105 epithelial cells were seeded on top of the
matrices. On day 15, the cultures were fixed in Zn-buffered formalin (Thermo) for
2 hours at 4oC before dehydration and embedding in paraffin.
Real-time qPCR
RNA was isolated using the RNAqueous-4PCR kit (Ambion). cDNA was
generated using oligo-dT primers and Superscript II Reverse Transcriptase (Life
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Technologies).

Real-time PCR was performed using validated SYBR Green

primers and ABI7000 and ABI StepOne instruments (Applied Biosystems).
FACS
Cells were labeled with CFDA-SE (Invitrogen; 1 or 0.1 μM for epithelial
cells or fibroblasts, respectively) for 30 minutes at 37oC, quenched for 30 minutes
at 37oC, trypsinized and seeded into co- or mono-cultures. After 72 hours, the
cells were trypsinized, resuspended in PBS with 1% BSA and 0.01% sodium
azide. Samples were analyzed on a FACScalibur (BD) or Accuri (BD). Data were
analyzed using FlowJo (Treestar).
Cytokine array
3x105 cells were seeded per 6 cm dish and grown in 5 mL DMEM with
10% FBS (HyClone) and 1x penicillin/streptomycin. Each culture condition was
carried out in duplicate. After 72 hours, conditioned media were collected, frozen
and stored at -80oC. The relative concentration of 42 cytokines was measured
using the Human cytokine array G3 (Raybiotech).
ELISA
Cytokine levels in culture supernatants were quantified using the Human
IL-6 ELISA MAX and Human CCL5 (RANTES) ELISA MAX kits (BioLegend)
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according to the manufacturer’s instructions. Absorbance was measured on the
Sunrise Microplate Reader (TECAN).
Histology
ESCC tissue samples were obtained as surgical biopsies from Kagoshima
University Hospital, as described previously (Natsuizaka et al., 2014). The clinical
materials were obtained from informed-consent patients according to the
Institutional

Review

Board

standards

and

guidelines.

IHC

and

immunofluorescence were performed as described previously (Karakasheva et
al., 2015).
Xenograft tumor growth studies
All animal studies were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Pennsylvania. A total of 6x10 6 cells (all
epithelial, or 5x106 epithelial cells with 106 fibroblasts) resuspended in 50 μl
matrigel were injected subcutaneously into rear flanks of female athymic nude
mice (6-10 weeks old, Taconic). Tumors were measured twice a week after
becoming palpable. For therapeutic studies, tocilizumab or human IgG control
were delivered intraperitoneally at 10mg/kg three times a week; maraviroc or
vehicle control (DMSO) were delivered intraperitoneally at 10mg/kg daily.

43

Statistical analysis
Student’s t-test was used to determine significance. ANOVA analysis was
used to determine significance for multi-parameter comparisons. Unless noted
otherwise, the p-values are listed on graphs. All analyses were performed in R
version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
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Figures and figure legends
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Figure 2-1: Direct interaction between tumor cells and CAFs induces changes in
cell biology. (A) qPCR analysis of gene expression in ESCC cells (TE11) co-cultured
with CAFs (FEF3303), compared to mono-culture (n=2/group; *p<0.05). (B) Relative
proliferation rates of ESCC cells (TE1, TE6, TE11, HCE7) and CAFs (FEF3, FEF3303)
in mono- or co-culture, measured by CFDA-SE fluorescence dilution (n=3/group; *p=104

, 10-6, 10-5, 10-6, 0.007; **p<10-3; ***p<10-2). (C) Representative images of 3D

organotypic cultures where epithelial cells have been seeded alone (TE11) or mixed
directly with CAFs (TE11+FEF3303) (n=3/group). Number of nucleated epithelial layers
and relative invasive area are quantified. (D) Growth kinetics of subcutaneous xenograft
tumors formed by ESCC cells alone or co-injected with CAFs (n=4/cohort; *p<0.05). Pvalues calculated via Student’s t-test, p≤0.05 considered statistically significant.
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Figure 2

48

Figure 2-2: IL-6 and RANTES are potential mediators of cross-talk between tumor
cells and CAFs in ESCC. (A) Representative results of the cytokine array conducted on
conditioned media from mono- and co-cultures of ESCC cells (TE1, TE6, TE11, HCE7)
and CAFs (FEF3, FEF3303) (n=2/group). (B) Concentration of IL-6 and RANTES in
conditioned media from mono- and co-culture of ESCC cells and CAFs, measured by
ELISA (n=3/group). P-values calculated via Student’s t-test, p≤0.05 considered
statistically significant.
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Figure 3

Figure 2-3: IL-6 and RANTES are overexpressed in epithelial and stromal
compartments of ESCC. (A, B) Representative images of normal esophagus and
ESCC stained immunohistochemically for IL-6 or RANTES (n=40). Histopathological
scoring results are shown on the right. P-values calculated via Student’s t-test, p≤0.05
considered statistically significant.
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Figure 4

Figure 2-4: Quality-control of the IL-6 and RANTES-knockout subclones of TE11
ESCC cell line. Levels of corresponding cytokines in cell culture conditioned media
were measured by ELISA and compared to wild-type TE11 conditioned medium, as well
as to DMEM (negative control). Results shown are for the subclones at passage 3 posttransfection with the CRISPR/Cas9 construct. The stability of knockout was confirmed by
ELISA for up to passage 12 post-transfection (n=3 wells/clone). P-values calculated via
Student’s t-test, p≤0.05 considered statistically significant.
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Figure 5
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Figure 2-5: Tumor cell-derived IL-6 promotes tumorigenic properties in ESCC. (A)
Representative images of 3D organotypic cultures (Hematoxylin-Eosin stained paraffinembedded sections) formed by wild-type or IL-6 knockout TE11 cells (n=2/clone). (B)
Representative images of 3D ESCC organoids (brightfield and Hematoxylin-Eosin
staining of paraffin-embedded sections) formed by wild-type or IL-6 knockout TE11 cells.
Organoid size is quantified as relative cross-section area, organoid shape quantified as
deviation from elliptical shape (n=4/clone). (C) Growth kinetics of subcutaneous
xenograft tumors formed by wild-type or IL-6 knockout TE11 cells (n=6/clone; *p≤0.01).
P-values calculated via Student’s t-test, p≤0.05 considered statistically significant.
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Figure 6

Figure 2-6: Targeting IL-6 is a promising novel approach for ESCC therapy. (A)
Growth kinetics of subcutaneous ESCC xenograft tumors (TE11+FEF3303) treated with
Tocilizumab or isotype control (i.c.) antibody (n=10/cohort, results from one
representative study out of three shown; *p=0.009, 0.004, 0.0002). (B) Representative
images of tumor sections from (A) stained for pSTAT3 and pERK. (C) Quantification of
staining from (B). P-values calculated via Student’s t-test, p≤0.05 considered statistically
significant.
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Figure 7
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Figure 2-7: Tumor cell-derived RANTES promotes tumorigenic properties in ESCC.
(A) Representative images of 3D organotypic cultures (Hematoxylin-Eosin stained
paraffin-embedded sections) formed by wild-type or RANTES knockout TE11 cells
(n=2/clone). (B) Representative images of 3D ESCC organoids (brightfield and
Hematoxylin-Eosin staining of paraffin-embedded sections) formed by wild-type or
RANTES knockout TE11 cells. Organoid size is quantified as relative cross-section area,
organoid shape quantified as deviation from elliptical shape (n=4/clone). (C) Growth
kinetics of subcutaneous xenograft tumors formed by wild-type or RANTES knockout
TE11 cells (n=6/clone; *p≤0.05). P-values calculated via Student’s t-test, p≤0.05
considered statistically significant.
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Figure 8

Figure 2-8: Targeting RANTES is a promising novel approach for ESCC therapy.
(A) Growth kinetics of subcutaneous ESCC xenograft tumors (TE11+FEF3303) treated
with maraviroc or DMSO (n=4/cohort; *p=0.02). (B) Representative images of tumor
sections from (A) stained for pERK1/2 and pSTAT3. (C) Quantification of staining from
(B). P-values calculated via Student’s t-test, p≤0.05 considered statistically significant.
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Figure 9

Figure 2-9: Co-inhibition of IL-6 and RANTES signaling may be superior to monotherapy. (A) Representative images of 3D organotypic ESCC cultures treated with
tocilizumab, maraviroc or a combination of both (Hematoxylin-Eosin staining;
n=2/condition). (B) Quantification of images from (A). P-values calculated via Student’s ttest, p≤0.05 considered statistically significant.
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Figure 10
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Figure 2-10: STAT3 and ERK1/2 signaling mediate ESCC tumorigenesis in vitro.
(A) Representative images of 3D organotypic ESCC cultures (Hematoxylin-Eosin,
cleaved caspase 3 and Ki-67 staining; arrows indicate cleaved caspase 3-positive cells;
n=4/condition). (B) Quantification of images from (A). P-values calculated via Student’s ttest, p≤0.05 considered statistically significant.
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Figure 11

Figure 2-11: Potential of targeting IL-6 in multiple types of cancer. (A) Kaplan-Meier
survival analysis based on differential expression of IL-6 and IL-6R in esophageal cancer
and pan-cancer (RNAseq data, TCGA; p=0.0065 (esophageal), 3x10-11 (pan-cancer)).
(B) Representative images of normal oral mucosa and head and neck cancer stained for
IL-6 by immunohistochemistry, with quantification. (C) Representative images of normal
gastric mucosa gastric adenocarcinoma stained for IL-6 by immunohistochemistry, with
quantification. P-values calculated via Student’s t-test, p≤0.05 considered statistically
significant. (Data used with permission from Eric Lin).
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Tables and table legends
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Table 1
Cancer
Sponsor
Tocilizumab (IL-6Rα antibody)
Ovarian
Leiden University
Medical Center

Treatment modality
Combination (Carbo/Caelyx or
Carbo/Doxorubicin)

Unresectable
Herlev Hospital
Combination (gemcitabine/nabpancreatic
paclitaxel)
carcinoma
Chronic
Hoffmann-La Roche
Combination (standard
lymphocytic
premedication, obinutuzumab +
leukemia
chlorambucil
Maraviroc (CCR5 antagonist)
Metastatic
National Center
Single agent
colorectal
for Tumor Diseases,
cancer
Heidelberg
Mogamulizumab/ KW-0761 (CCR4 antibody)
Adult
T-Cell Kyowa Hakko Kirin
Single agent
Leukemia and Company, Limited
Lymphoma,
adult
Peripheral
T-Cell
Lymphoma
Peripheral
Kyowa Hakko Kirin
Single agent
T-Cell
Pharma, Inc.
Lymphoma
Peripheral
Kyowa Hakko Kirin
Single agent
T-Cell
Pharma, Inc.
Lymphoma
Peripheral
Kyowa Hakko Kirin
Single agent
T/NK-cell
Company, Limited
Lymphoma
Cutaneous
Kyowa Hakko Kirin
Single agent, compared to vorinostat
T-Cell
Pharma, Inc.
Lymphoma
Adult
T-cell Kyowa Hakko Kirin
Single agent
LeukemiaCompany, Limited
lymphoma
Adult
T-cell Kyowa Hakko Kirin
Single agent, compared to
LeukemiaPharma, Inc.
investigator's choice (pralatrexate;
lymphoma
gemcitabine/oxaliplatin;
dexamethasone/cisplatin/cytarabine)
Adult
T-cell
Leukemialymphoma

Kyowa Hakko Kirin
Company, Limited

Single agent, compared to
VCAP/AMP/VECP(mLSG15)

Phase
I/II

NCT01637532

II

NCT02767557

I

NCT02336048

I

NCT01736813

I

I/II

NCT00888927

II

NCT01611142

II

NCT01192984

III

NCT01728805

II

NCT00920790

II

NCT01626664

II

NCT01173887

Table 2-1: Clinical trials targeting IL-6 or RANTES signaling in cancer.
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Identifier

Chapter 3 CHAPTER 3: Cytokine regulation of the immunosuppressive
microenvironment in ESCC

The data in chapter 3 have been published in Cancer Research.
Karakasheva T., Waldron T. et al., 2015. Cancer Research Oct 1; 75(19):4074-85
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Abstract
Myeloid derived suppressor cells (MDSCs) are an immunosuppressive
population of immature myeloid cells found in advanced stage cancer patients and
mouse tumor models.

Production of inducible nitric oxide synthase (iNOS) and

arginase, as well as other suppressive mechanisms, allow MDSCs to suppress T cellmediated tumor clearance and foster tumor progression, in addition to other
mechanisms such as fostering angiogenesis and inducing activation of fibroblasts. We
have identified CD38 as playing a vital role in MDSCs biology in a murine model of
ESCC.

CD38 belongs to the ADP-ribosyl cyclase family and possesses both

ectoenzyme and receptor functions. It has been described to function in early myeloid
cell differentiation, cell activation and neutrophil chemotaxis. We found that CD38
expression in MDSCs is evident in several mouse tumor models, and CD38high MDSCs
are more immature than CD38low or CD38neg MDSCs, suggesting a potential role for
CD38 in the maturation halt found in MDSC populations. CD38high MDSCs also possess
a greater capacity to suppress activated T cells, and promote tumor growth to a greater
degree than CD38low MDSCs, likely as a result of increased iNOS production. Tumorderived factors, including IL-6, IGFBP-3 and CXCL16 (identified by us), play a role in the
induction of CD38 expression.

This work may have implications for use of

FDA-

approved anti-CD38 therapy in patients with solid tumors where MDSCs are
upregulated.
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Introduction
The immune system (both innate and adaptive) plays an essential role in limiting
tumor growth; therefore, tumor progression requires escape from immune surveillance.
One of the mechanisms that allows for tumor escape is the activation and expansion of
immunosuppressive cell populations, including but not limited to, regulatory T cells
(Tregs) and myeloid derived suppressor cells (MDSCs) (Schreiber et al., 2011), the latter
also referred to as immature myeloid cells. Certain therapeutics have been
demonstrated to have potential efficacy against MDSCs (Waldron, T J, Quatromoni G J,
Karakasheva, T A, Singhal, S, Rustgi, 2013); however, the need for more selective antiMDSC therapeutics remains.
MDSCs have been observed in a number of mouse tumor models and represent
a heterogeneous population of immature monocytes, macrophages, granulocytes, and
dendritic cells that are identified by their CD11b+Gr-1+ phenotype in mice. The first
human MDSC population was identified in head and neck cancer (Pak et al., 1995), and
has since been since documented in cancers of the esophagus (Gabitass et al., 2011),
stomach (Gabitass et al., 2011), pancreas (Gabitass et al., 2011; Schmielau and Finn,
2001), lung (Liu et al., 2010), kidney (Zea et al., 2005), colon (Schmielau and Finn,
2001), skin (melanoma) (Filipazzi et al., 2007), prostate (Vuk-Pavlović et al., 2010), and
breast (Schmielau and Finn, 2001). The immunophenotype of human MDSCs varies
(Greten et al., 2011), however, their immunosuppressive mechanisms match those
found in murine CD11b+Gr-1+ MDSC populations.
MDSCs induce immune suppression primarily through the inhibition of T cellmediated tumor clearance (Gabrilovich and Nagaraj, 2009), but can also promote
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inhibition of NK cells (Li et al., 2009) and activation of Tregs (Huang et al., 2006; Serafini
et al., 2008). Arginase-1 (ARG1) and inducible nitric oxide synthase-2 (iNOS) provide
the bulk of the enzymatic activity required for MDSCs to suppress proliferation and
activation of T cells (Gabrilovich and Nagaraj, 2009). ARG1 deprives T cells of arginine
by converting L-arginine into urea and L-ornithine, thereby leading to reduced
expression of CD3ζ chain, which renders T cells unable to respond to activation signals
(Rodriguez et al., 2003, 2004). iNOS inhibits T cell function by a variety of mechanisms,
including the inhibition of JAK3/STAT5 signaling (Bingisser et al., 1998), MHC Class II
expression (Harari and Liao, 2004) and induction of apoptosis (Rivoltini et al., 2002).
CD38 expression is a common characteristic to several immunosuppressive cell
types.

Foxp3+CD25+CD4+ Tregs expressing high levels of CD38 possess greater

immunosuppressive activity than CD38low Tregs (Patton et al., 2011). CD38+CD8+ T cells
suppress proliferation of CD4+ effector T cells, which requires secretion of IFNγ and cellto-cell contact (Bahri et al., 2012). Similarly, CD19+CD24hiCD38hi B cells inhibit the
differentiation of T helper 1 cells through an IL-10-dependent mechanism, and their
dysfunction may play a role in autoimmune disorders such as systemic lupus
erythematosus (Blair et al., 2010).
CD38 is a member of the ribosyl cyclase family and is expressed on the surface
of diverse immune cells, including B cells, T cells, NK cells and myeloid cells (Malavasi
et al., 2008a). CD38 possesses independent ectoenzyme and receptor functions. As an
ectozyme, CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR),
converting NAD+ to ADP-ribose (ADPR), as well as cADPR into ADPR (Lee, 2012;
Malavasi et al., 2008a). Furthermore, at acidic pH, CD38 catalyzes the synthesis and
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hydrolysis of nicotinic acid adenine dinucleotide phosphate (NAADP) (Lee, 2012;
Malavasi et al., 2008a). Both reactions are important for calcium signaling, specifically
for mobilization of intracellular Ca2+ (Lee, 2012). Receptor activity of CD38 has been
documented in several immune cell types, where it is dependent on localization to the
lipid rafts and association with professional signaling complexes (Malavasi et al., 2008a).
In both mouse and human myeloid cells, ligation of CD38 leads to suppressed growth
and survival leading to loss of the most differentiated immune populations (Todisco et
al., 2000).
We have identified CD38 as a novel marker for MDSCs that possesses greater
immunosuppressive capacity, thereby promoting tumor growth in vivo. Mechanistically,
CD38 promotes expansion of the monocytic MDSC population and regulates expression
of the effector molecule iNOS by these cells. Importantly, we have established for the
first time that several cytokines, specifically IFNg, TNFa, IGFBP-3, CXCL16, and IL-6,
are capable of inducing CD38 expression in MDSCs. Finally, we have demonstrated that
administration of an anti-CD38 monoclonal antibody slows disease progression in tumorbearing mice.
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Results
CD38high MDSCs possess greater immunosuppressive and tumor-promoting
capacity than CD38low MDSCs
We have previously demonstrated that MDSCs play a fundamental role in tumor
initiation and progression in a spontaneous genetic mouse model of ESCC (L2Cre;p120f/f) (Stairs et al., 2011), and our next goal was to identify genes associated with
an immature myeloid phenotype that contribute to the tumor promoting activities of
MDSCs. To that end, we performed microarray analysis of splenic MDSCs from tumorbearing L2-Cre;p120f/f mice and age-matched littermate controls and identified Cd38
(ranked fifth highest among all genes tested as a candidate gene of interest), as it has
roles in both innate and adaptive immunity in mice and humans, including, but not limited
to chemotaxis of murine and human neutrophils, early myeloid differentiation and
lymphoid cell activation (Karakasheva et al., 2015).
These findings led us to the hypothesis that CD38high MDSCs possess greater
immunosuppressive potential than CD38low MDSCs. To test our hypothesis, we FACSsorted both CD38high and CD38low populations from mice bearing ESCC tumors
generated by flank injections of the HNM007 cell line in syngeneic C57BL/6 recipients
and tested their capacity to suppress OT-1 T cell growth following stimulation with
cognate antigen.

The capacity of total CD11b+Gr-1+, CD11b+Gr-1+CD38low, and

CD11b+Gr-1+CD38high cells to suppress T cell proliferation after stimulation was tested.
CD38high MDSCs demonstrated significantly greater T cell suppressive capacity,
compared to their CD38low counterparts (Fig. 1A), at 2:1 OT-1 to MDSC ratio, while a
trend of increased suppression was observed at 1:1 and 4:1 ratios.
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Next, we evaluated the impact of coinjection of CD38high MDSCs with HNM007
cells on tumor growth. Tumor volumes in the CD38High group were significantly larger
than the CD38Low tumors when measured on days 6 and 10 (Fig. 1B), and larger than
control HNM007 tumors at days 8, 10 and 13 (Fig. 1B). No differences in size were
detected between the CD38Low and control HNM007 tumors. These results suggest that
CD38high MDSCs possess greater tumor-promoting capacity than CD38low MDSCs in
vivo.
We next investigated whether CD38 is required for immunosuppressive function
of MDSCs. We therefore tested the capacity of Cd38-/- and Cd38+/+ (wt) CD11b+Gr-1+
cells sorted from mice bearing HNM007 tumors to suppress growth of OT-1 T cells
following antigen stimulation and found that Cd38-/- CD11b+Gr-1+ cells exhibited
significantly reduced immunosuppressive capacity at 1:1 and 4:1 OT-1 to MDSC ratio
(Fig. 1C).
IFNγ, TNFα, CXCL16, IGFBP-3 and IL-6 induce the expression of CD38
We have observed that unlike the HNM007 ESCC cell line, the tumors generated
by flank injection of the AKR ESCC line do not induce high expression of CD38 on the
surface of MDSCs (Fig. 2). This prompted us to employ these two cell lines to better
understand the tumor cell-specific signaling pathways that result in increased expression
of CD38. We performed ex vivo differentiation of bone marrow using GM-CSF, IL-4 (the
cytokines required for generation of CD11b+Gr-1+ cells from bone marrow progenitors
(Youn et al., 2008)) and either HNM007 or AKR conditioned media.

HNM007

conditioned medium induced cells to express CD38 while AKR conditioned medium did
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not (Fig. 3B). Since IFNγ and TNFα are key components of the pro-inflammatory milieu
and both are known activators of CD38 transcription (Malavasi et al., 2008a), we
performed an ex vivo differentiation assay with the addition of IFNγ, TNFα, or both and
found that both factors induced CD38 expression in the CD11b+Gr-1+ population, while
the combination of IFNγ and TNFα induced the most profound effect (Fig. 3B). We
subsequently performed a cytokine array using media collected from the ex vivo
differentiation experiments and compared the levels of 62 cytokines present in the
culture medium derived from HNM007 conditioned medium to culture medium derived
from AKR conditioned medium.

Several factors including CXCL16, IGFBP-3 and

RANTES were present at higher levels in the HNM007 conditioned medium samples
after 24 hours in culture (Table 1). CXCL16 and IGFBP-3 levels were maintained at
higher levels in HNM007 conditioned media-containing cultures after 120 hours (Table
1), suggesting that either of these two factors, or both, may play a role in induction of
CD38. In addition, the pro-inflammatory cytokine IL-6, a predicted activator of CD38
transcription (Malavasi et al., 2008b), was elevated in HNM007 conditioned mediacontaining cultures after 24 and 120 hours, albeit not as dramatically as CXCL16 or
IGFBP-3 (Table 1). We tested next the capacity of recombinant IL-6, CXCL16 and
IGFBP3 alone or in combination to increase CD38 expression in our ex vivo
differentiation experiments. Addition of the combination of IL-6, CXCL16 and IGFBP3
was able to induce CD38 expression in MDSC cultured with AKR conditioned medium
(Fig. 4B). Nevertheless, the most potent induction of CD38 expression was observed
when IFNγ and TNFα were added to the culture. The importance of IL-6 in ESCC
pathogenesis is elucidated in Chapter 2 of this thesis.
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Cross-linking of CD38 by an agonistic antibody impairs expansion and survival of
CD11b+Gr1+ cells in vitro and suppresses tumor growth in vivo
In order to test whether cross-linking of CD38 with a monoclonal antibody has an
effect on MDSC function(s), we performed a colony-formation assay. CD11b+Gr-1+ cells
were isolated from the spleens of diseased L2-cre;p120-/- mice and cultured in
methylcellulose-based medium in the presence of an anti-CD38 monoclonal antibody
(NIM-R5) or an isotype control. Addition of an anti-CD38 antibody inhibited the growth of
colonies from sorted splenic CD11b+Gr-1+ cells (Fig. 5A and 5B). The effect of the antiCD38 antibody remained the same regardless of whether splenocytes were pre-sorted
(Fig. 5A and 5B). These data demonstrate that anti-CD38 treatment inhibits MDSC
proliferation and survival in vitro independent of stromal support. We similarly tested the
effect of anti-CD38 treatment in suspension culture. FACS-sorted CD11b+Gr-1+ cells
survive only a few days in culture, but their survival is significantly reduced in the
presence of anti-CD38 antibody (Fig. 5C). We have also tested whether cross-linking of
CD38 inhibits the accumulation of CD11b+Gr-1+CD38high cells produced by our ex vivo
culture of bone marrow in the presence of tumor cell conditioned medium, IL-4 and GMCSF. Using a CD38 antibody (clone 90) different from NIM-R5, we observed a dosedependent decrease in the CD38 expression within the CD11b+Gr-1+ population (Fig.
5D). Given that the proportion of CD11b+Gr-1+ cells within the bone marrow culture
remained consistent (25-30%; data not shown) the CD38 expression data demonstrate
that the CD11b+Gr-1+CD38high population is reduced as a result of CD38 cross-linking.
Lastly, we have attempted a pilot study investigating the effect of CD38 antibody
treatment on tumor growth rate in vivo in a subcutaneous transplant model of ESCC.
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HNM007 tumor-bearing mice were treated every 48 hours with anti-CD38 (NIM-R5) or
isotype control (IgG2a) antibody, starting on day 5 post-injection. We have observed a
significant decrease in tumor volume in the NIM-R5-treated cohort, compared to the
IgG2a-treated cohort (Fig. 5E). These data demonstrate the importance of CD38 for
MDSC-mediated tumor progression, as well as suggest targeting CD38 as an
experimental approach to ESCC therapy.
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Discussion
We have identified CD38 as a functional marker of MDSCs with higher
immunosuppressive capacity. Yet, we did not know what factors are responsible for
induction of CD38 expression in this population. Interestingly, two different ESCC cell
lines used in our studies exhibited differential capacities to induce expansion of a
CD11b+Gr-1+CD38high MDSC population, thereby suggesting that the tumor cells are
responsible for initiating the signaling cascade that results in the increased CD38
expression on MDSCs. Based upon our ex vivo studies, the tumor-derived signals may
act directly on immature myeloid cell populations present in hematopoietic tissues to
promote CD38 expression.
Several factors are likely to be responsible for activating CD38 expression,
including IFNγ, TNFα, IL-6, IGFBP-3 and CXCL16. Transcriptional regulation of CD38
expression by both IFNγ and TNFα has been reported (Malavasi et al., 2008a), and we
demonstrated that both are capable of inducing cultured bone marrow derived
CD11b+Gr-1+ cells to express CD38. As both IFNγ and TNFα are often produced during
chronic inflammation, they may be primary inducers of CD38 expression and the
resulting changes in immature myeloid cell populations (Fig. 6). In fact, use of a TNFα
inhibitor (etanercept) has been demonstrated to inhibit suppressive capacity of MDSCs
and induce differentiation in a murine model of chronic inflammation (Sade-Feldman et
al., 2013). Coupled with our observation that TNFα potently induces CD38 expression,
the finding that MDSCs from both Cd38-/- and Tnf-/- mice exhibit reduced iNOS levels
(Levy et al., 2012; Mayo et al., 2008) suggests that TNFα likely activates CD38
expression in MDSCs, thereby leading to the induction of iNOS expression in vivo.
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IL-6 is a major regulator of activation of STAT3 and a key transcriptional factor
for establishment of immunosuppressive microenvironment within the tumor (Kortylewski
et al., 2005). Importantly, a recent report demonstrated correlation between increased
serum levels of IL-6 and poor prognosis, as well as with the expansion of MDSC-like
population (CD11b+CD14+HLA-DR-) in peripheral blood of ESCC patients (Chen et al.,
2014). It has been shown that overabundance of activated STAT3 stalls differentiation of
myeloid cells, resulting in expansion of the immature myeloid cell pool (Nefedova et al.,
2004). In MDSCs, STAT3 activation enhances production of the S100A8/A9 proinflammatory factors, which also contribute to maintenance of a reduced differentiation
state (Cheng et al., 2008; Sinha et al., 2008). These data are in agreement with our
observation that IL-6 can promote CD38 expression on MDSCs generated ex vivo, since
CD38high MDSCs are less differentiated than their CD38low counterpart (Karakasheva et
al., 2015).

At the same time, in lymph nodes, B cell-derived IL-6 prompts resident

macrophages to secrete CXCL10, which promotes differentiation of B cells into
CD138+CD38+ plasma cells (Xu et al., 2012). This report supports our observation that
IL-6 can induce CD38 expression; it also implies that in our ex vivo differentiation system
this process may also be mediated by bone marrow-derived macrophages.
Our finding of a CXCL16-mediated response in MDSC has not been described
previously. However, it is interesting to note that CXCL16 is induced by IFNγ and TNFα
(Abel et al., 2004). Dendritic cells express CXCL16, which in turn is found in T cell
replete areas of the spleen and lymph nodes (Matloubian et al., 2000). CXCL16 binds its
cognate receptor, CXCR6, and induces the migration of T and NK cell populations
(Matloubian et al., 2000). Thus, CXCL16 is found in tissues where MDSCs and T cells
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may interact and may serve to recruit T cells to these regions. If CXCL16 can also
induce MDSCs to adopt a more immunosuppressive phenotype, as we suggest, it could
greatly contribute to T cell suppression.
IGFBP-3 is most widely known as the main binding partner for the insulin-like
growth factors (IGFs), and as a part of this complex IGFBP-3 can stimulate cell
proliferation, differentiation, cell survival and enhanced metabolic activity. However, the
same signaling complex can suppress proliferation and induce apoptosis. Furthermore,
IGFBP-3 can act independently of IGF either by entering the nucleus and directly binding
DNA or by binding to several receptors on the cell surface, for example TGFβRV (JogieBrahim et al., 2009). The potential effects of IGFBP-3 on hematopoietic cells have not
been investigated, however, there are several reports addressing its role in cancer. For
example, IGFBP-3-induced increase in intracellular Ca2+ levels has been reported in
breast cancer and myoblast cell lines (Seurin et al., 2013). This area certainly requires
additional investigation, but it is plausible to hypothesize that since Ca2+ signaling is
important for multiple immunomodulatory processes (Sochorová et al., 2009; Vellenga et
al., 1993; Vukcevic et al., 2010), IGFBP-3 may potentiate expansion of the more
immunosuppressive CD38High MDSCs.
The chemokine RANTES was also associated with conditions promoting CD38
expression in the ex vivo differentiation culture (Table 1). We have yet to validate these
results with recombinant RANTES, however, there is published evidence supporting its
role in immunosuppressive capacity of MDSCs. Interestingly, monocytic MDSCs from
tumor-bearing Rantes-/- mice were shown to be less immunosuppressive than MDSCs
from Rantes+/+ mice (Zhang et al., 2013). Furthermore, this phenotype was attributed to
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reduced production of iNOS by these cells (Zhang et al., 2013). These data seem to
correlate with our findings of monocytic MDSCs relying on iNOS for their
immunosuppressive capacity (Karakasheva et al., 2015).
We also demonstrate here that targeting CD38 with a monoclonal antibody
resulted in suppressed tumor growth rate in vivo; therefore, anti-CD38 therapy may
represent a novel approach to targeting this immunosuppressive population in cancer
treatment strategies. Recently, an anti-CD38 monoclonal antibody (daratumumab) was
shown to be efficient in treatment of multiple myeloma (MM) in pre-clinical studies (de
Weers et al., 2011). Moreover, in early-stage clinical trials daratumumab was found to be
effective in patients with relapsed MM both as a single agent and in combination
therapy, which resulted in its approval for MM and designation of the drug as
“breakthrough therapy” by the US FDA (Laubach et al., 2014). A similar approach may
allow ablation of MDSCs in patients with advanced stage solid cancer, and thus, may be
suitable as an adjuvant to conventional therapies.
The expression pattern of CD38 in a broad range of cell types can raise a
concern about potential adverse effects of anti-CD38 therapy (discussed in (Stevenson,
2006)), however, early clinical studies of daratumumab in MM have demonstrated an
acceptable safety profile, suggesting that an appropriate dosage and treatment schedule
allow for minimizing of the effects of targeting CD38 in normal tissue (Laubach et al.,
2014). In addition, it is known that daratumumab induces killing of CD38-expressing cells
through antibody-dependent cell-mediated cytotoxicity (ADCC) (Phipps et al., 2015). The
main caveat of such a mechanism is that it only works on cells expressing high copy
numbers of the target antigen, therefore, certain populations may be left unharmed. This
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emphasizes the need for development of a new generation of CD38-targeting
therapeutics. One of the options would be to conjugate the antibody to a cytotoxic drug
that would be cleaved upon the internalization of CD38. Another promising avenue is
development of bispecific antibodies, which will allow for a more selective targeting of
immunosuppressive populations. Finally, the efficacy and specificity of CD38 bindinginduced ADCC can be fine-tuned via modifications in the Fc domain of the antibody (Liu
et al., 2014).
Like the robust immunosuppressive characteristics of CD38high MDSCs that we
describe in this study, CD38high regulatory T cells possess enhanced suppressive
potential compared to CD38low counterparts (Bahri et al., 2012; Patton et al., 2011). This
may indicate that the evolution of suppressive immune populations has selected for the
cells that are capable of expressing CD38. Furthermore, this suggests that anti-CD38
therapy may present the advantage of targeting several immunosuppressive cell types at
the same time.
We tested the effects of anti-CD38 monoclonal antibody (mAb) treatment in vitro
and observed a reduction in survival of CD11b+Gr-1+ cells sorted from the spleens of
tumor-bearing L2-cre;p120-/-. Furthermore, we demonstrated that ex vivo production of
CD11b+Gr-1+CD38high cells was inhibited by treatment with anti-CD38 mAb. While the
overall production of CD11b+Gr-1+ cells was unaffected, the reduction of CD11b+Gr1+CD38high population may provide the benefit of reducing numbers of the most
immunosuppressive MDSC population. In addition, our data suggest that the
CD11b+Gr-1+CD38high population likely possesses survival and self-renewal capacity
absent in the CD11b+Gr-1+CD38low populations. Anti-CD38 mAb treatment of sorted and
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unsorted splenocytes led to a loss of all CD11b+Gr-1+ cells, whereas control antibody
treated cultures were capable of colony formation and exhibited greater survival
potential. However, when bone marrow cultures were treated with anti-CD38 mAb, only
the CD11b+Gr-1+CD38high cells were lost, suggesting that a progenitor population
present in the bone marrow, but likely absent in the spleen, may be capable of
replenishing the CD11b+Gr-1+CD38low cell population.
The efficacy of immunotherapy has been demonstrated in several tumor types
(Brahmer et al., 2010, 2012; Hodi et al., 2010; Robert et al., 2013; Topalian et al., 2012).
Several of the most promising approaches function through impairment of T cell
suppression mediated by antigen-presenting cells, as in the case of anti-CTLA-4 therapy
(Ipilimumab) (Hodi et al., 2010; Robert et al., 2013), or suppression mediated by tumor
cells, as in anti-PD-1 therapy (Brahmer et al., 2010; Topalian et al., 2012). MDSCs
represent another facet of the T cell suppression repertoire found in cancer that merits
further investigation as a potential therapeutic target (Marigo et al., 2008). In this study,
we have identified CD38 as being suitable for potential MDSC targeting, and useful in
the identification of potently immunosuppressive MDSC populations. Thus, anti-CD38
monoclonal antibody therapy (de Weers et al., 2011) may hold potential for targeting
CD38-expressing MDSCs (Chillemi et al., 2013) in patients with solid tumors.
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Materials and methods
Cell lines and reagents
AKR and HNM007 mouse ESCC tumor lines have been described previously
(Opitz and Harada, 2002; Takaoka et al., 2004). Cells were maintained in DMEM + 10%
FBS and passaged or harvested at ~80% confluency. Recombinant mouse CXCL16,
GM-CSF, IGFBP-3, IL-4, IL-6 were purchased from Peprotech. TNFα was from R&D. 2mercaptoethanol was purchased from Sigma. Anti-CD38 monoclonal antibody (clone
NIM-R5) for in vitro and ex vivo studies was purchased from Abcam. Anti-CD38
monoclonal antibody (clone NIM-R5) for in vivo studies was a kind gift from Dr. Fabio
Malavasi. The isotype control antibody (rat IgG2a) was purchased from BioXcell.
Vendor

Cat. number

Antibody
Murine Gr-1 (PE)

BioLegend

108408

Murine Ly-6C (PerCP)

BioLegend

128027

Murine Ly-6G (FITC)

BioLegend

127605

Murine CD11b (APC)

BioLegend

101212

Murine CD38 (FITC)

BioLegend

102705

Murine CD45 (FITC)

BioLegend

103107

Flow cytometry and cell sorting
Single cell suspensions were prepared from mouse bone marrow or spleen by
mechanical disruption. Red blood cells were lysed, and the remaining leukocytes were
washed with PBS, and resuspended in PBS + 2% FBS. Samples were analyzed on a
FACScalibur (BD) or LSRII (BD). Cell sorting for multiple markers was performed on a
FACSAriaII (BD). Data were analyzed using FlowJo (Treestar).
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Generation of MDSCs
The Institutional Animal Care and Use Committee (IACUC) at the University of
Pennsylvania approved all animal studies. Mice were housed under a 12-hour light/dark
cycle and fed ad libitum. Three mouse ESCC models were used for production of
MDSCs. The first is the L2-Cre;p120ctnf/f mouse model, which has been described
previously by us and involves the conditional knockout of p120ctn in the squamous oral
cavity, esophagus and forestomach, resulting in invasive squamous cell cancer with
desmoplasia and the specific recruitment of MDSCs (Stairs et al., 2011). We used also
two syngeneic transplantation models utilizing the HNM007 and AKR esophageal
squamous cell carcinoma (ESCC) cell lines. HNM007 or AKR cells were subcutaneously
injected into C57BL/6J (Jackson Labs) and Cd38-/- mice (gift from Dr. Eduardo Chini).
Mice were aged until tumors reached a volume of 0.8cm3. Spleens and bone marrow
were harvested at euthanasia for MDSC isolation.
Colony formation and cell recovery assays
200,000 cells were seeded into 35 mm plates containing 1 ml MethoCult medium
(M3534; Stem Cell Technologies). Anti-CD38 monoclonal antibody and IgG2a isotype
control were used at 10ug/mL. Colonies were counted after 7 days. For recovery assays,
5x105 MDSCs were seeded in complete RPMI 1640 medium supplemented with
antibodies; cells were quantified by Trypan Blue exclusion using a Countess automated
cell counter (Invitrogen).
T cell suppression
CD11b+Gr-1+, CD11b+Gr-1+CD38low, and CD11b+Gr-1+CD38high cell populations
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were sorted by flow cytometry. Antigen-specific CD8+ T cell suppression was tested as
described previously (Stairs et al., 2011). Splenocytes from OT-1 mice were activated by
addition of the OVA peptide to culture medium. The cultures were pulsed with 3H-labeled
thymidine, and 3H incorporation was assessed 24 hours later to quantify cell proliferation
rates.
Ex vivo MDSC differentiation
The generation of MDSCs from bone marrow has been described previously
(Youn et al., 2008).

Bone marrow cells were isolated from femurs and tibias of

C57BL/6J mice, and the red blood cells were lysed. The remaining cells were seeded
into 24-well plates (1x106 per well) in RPMI + 10% FBS supplemented with 0.1 ng/ml
GM-CSF, 0.1 ng/ml IL-4, 50 uM 2-mercaptoethanol (Sigma), 10 ng/ml TNFα, 10 ng/ml
IFNγ, 100 ng/ml IL-6 100 ng/ml CXCL16, 100 ng/ml IGFBP-3, and 50% v/v of either
DMEM + 10% FBS or conditioned medium (CM) from HNM007 or AKR cells.

For

antibody treatment experiments, anti-CD38 monoclonal antibody and IgG2a isotype
control antibody were added at 10ug/ml. The cells were cultured at 37°C in 5% CO2
humidified atmosphere. On day 3 of culture the spent media were replaced with fresh
media supplemented with cytokines and CM. The cells were harvested on day 5 and
analyzed by flow cytometry.
Cytokine Array
Media from ex vivo differentiation cultures was collected and snap frozen after 1
or 5 days of culture. Array analysis was performed using the mouse cytokine array C3
(Raybiotech) according to the manufacturer’s protocol. Cytokines tested included Axl,
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BLC, CD30 Ligand, CD30, CD40, CRG-2, CTACK, CXCL16, Eotaxin-1, Eotaxin-2, Fas
Ligand, Fractalkine, G-CSF, GM-CSF, IFN-gamma, IGFBP-3, IGFBP-5, IGFBP-6, IL-1
beta, IL-10, IL-12 p40/p70, IL-12 p70, IL-13, IL-17, IL-1 alpha, IL-2, IL-3, IL-3 Rb, IL-4,
IL-5, IL-6, IL-9, KC/CXCL1, Leptin/OB, Leptin R, LIX, L-Selectin, Lymphotactin, MCP-1,
MCP-5, M-CSF, MIG, MIP-1 alpha, MIP-1 gamma, MIP-2, MIP-3 beta, MIP-3 alpha, PF4, P-Selectin, RANTES, SCF, SDF-1 alpha, sTNFRI, sTNFRII, TARC, TCA-3, TECK,
TIMP-1, TNF alpha, Thrombopoietin, VCAM-1, and VEGF-A. Quantification of results
was performed using the ImageJ protein array analyzer. Results were normalized to
positive controls to allow for comparison of relative expression levels.
ESCC/MDSC Co-transplantation
C57BL/6J recipient mice from Jackson Labs were injected subcutaneously with a
mixture of 2.5x105 syngeneic HNM007 tumor cells with either 2.5x105 CD38low or CD38hi
MDSCs obtained from HNM007 tumor-bearing C57BL/6J mice. Recipient mice injected
with 2.5x105 syngeneic HNM007 tumor cells alone served as controls. Measurements
were taken every 2-3 days once tumors became palpable.
Statistical analysis
The Student t-test was used to determine whether there is significant difference
between two experimental groups (P≤0.05 was considered statistically significant).
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Figures and figure legends
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Figure 1

Figure 3-1: CD38high MDSCs are more immunosuppressive and promote tumor
growth more efficiently than the CD38low MDSCs. (A) CD38high and CD38low MDSCs
from tumor-bearing p120-/- mice were used in a T-cell suppression assay (n=3; *,
P=0.0007). (B) C57BL/6 mice were injected with HNM007 cells in combination with
MDSCs (CD38high or CD38low) or alone (n= 5 per group). Tumor volumes were compared
between the CD38high and CD38low groups (*, P=0.004 and 0.03), and between CD38high
and control HNM007 tumors (**, P= 0.01, 0.003, and 0.01). (C) Splenic MDSCs from
HNM007 tumor-bearing Cd38-/- or wt mice were used in a T-cell suppression assay (*,
P=0.003 and 0.04). P-values calculated via Student’s t-test, p≤0.05 considered
statistically significant.

85

Figure 2

Figure 3-2: HNM007, but not AKR ESCC cell line promotes expansion of CD38high
MDSCs. Splenocytes from AKR or HNM007 syngeneic subcutaneous transplant tumorbearing mice were analyzed by flow cytometry. CD38 expression levels on the
CD11b+Gr-1+ subpopulation are shown as histograms.
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Figure 3

Figure 3-3: HNM007 conditioned medium, IFNγ and TNFα induce CD38 expression
in an ex vivo differentiation model. (A) Scheme of the ex vivo differentiation assay:
bone marrow (BM) extracted from naïve C57BL/6 mice is cultured for 120 hours in the
presence of conditioned media (CM) from either AKR or HNM007 cell lines,
supplemented with a cocktail of cytokines. (B) CD38 expression in CD11b+Gr-1+ cells
from ex vivo differentiation cultures was tested by FACS (MFI = mean fluorescence
intensity; n=3; *P=10-4; **P=6x10-4; ***P=2.5x10-5). P-values calculated via Student’s ttest, p≤0.05 considered statistically significant.
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Figure 4

Figure 3-4: IL-6, IGFBP3 and CXCL16 are novel regulators of CD38 expression in
an ex vivo differentiation model. (A) Scheme of the ex vivo differentiation model
assay, followed by a cytokine array. (B) CD38 expression in CD11b+Gr-1+ cells from ex
vivo differentiation cultures was tested by FACS (MFI = mean fluorescence intensity;
n=3; *P=0.05; **P=0.005). P-values calculated via Student’s t-test, p≤0.05 considered
statistically significant.
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Figure 5
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Figure 3-5: Anti-CD38 monoclonal antibody inhibits Gr-1+CD11b+ expansion and
survival. (A) Colony formation of sorted Gr-1+CD11b+ from 6-8 month old p120-/- mice
grown in methylcellulose-based medium containing cytokines for the detection of
granulocyte-macrophage progenitors (CFU-GM, CFU-G, CFU-M).

Colonies were

counted following treatment with anti-CD38 monoclonal antibody (NIMR-5) or isotype
(IgG2a) control (10ug/ml) for 7 days. Results are representative of two different
experiments performed in triplicate. (* p=4x10-5) (B) Colonies observed after 7 days of
culture with anti-CD38 or isotype control. (C) Cell recovery of sorted Gr-1+CD11b+ from
p120-/- mice.

Gr-1+CD11b+ cells were isolated, cultured in RPMI with anti-CD38 or

isotype control antibody, and quantified at indicated time points. (* p=0.0005, **p=5x10-7)
(D) Ex vivo differentiation of wt bone marrow in the presence of anti-CD38 or isotype
control antibody. Cells were cultured for 5 days, and CD38 expression (detected using
anti-CD38 clone 90) on the surface of CD45+7-AAD-Gr-1+CD11b+ was measured by flow
cytometry (MFI = mean fluorescence intensity; * p=0.005, ** p=0.0005). Each treatment
was performed in triplicate. P-values calculated via Student’s t-test, p≤0.05 considered
statistically significant.
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Figure 6

Figure 3-6: Model. In mice, tumor progression leads to MDSC expansion. Tumor
progression leads to amplified signals (such as cytokines) reaching MDSCs, which
induces a differentiation halt and expansion of CD38high MDSCs with enhanced
immunosuppressive capacity [mediated by iNOS, which produces nitric oxide (NO)].
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Tables and table legends
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Table 1

Fold-change (HNM007/AKR)
Cytokine
24h

120h

Axl

5.44

-

BLC

3.83

-

CTACK

2.77

-

was performed with media from ex vivo

CXCL16

33.4

7.36

differentiation cultures (24 or 120 hours).

Eotaxin

4.83

-

G-CSF

4.39

-

GM-CSF

-

8.96

IGFBP-3

9.98

14.04

IGFBP-6

0.08

0.09

IL-3Rb

2.25

-

IL-6

2.11

2.20

KC

-

3.14

LIX

3.52

3.25

MCP-5

0.38

0.41

MIG

0.47

-

MIP-3b

0.11

-

P-selectin

-

4.82

RANTES

8.97

2.05

sTNF RII

0.34

-

VCAM-1

0.37

-

-

3.18

Table
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differentially
bone
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differentiation cultures associated with
high CD38 expression. Cytokine array

Each

cytokine

Difference

VEGF

Cytokines

in

tested

in

normalized

duplicate.
expression

between HNM007 and AKR groups is
shown.
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Chapter 4 CHAPTER 4: Thesis summary and discussion

94

The focus of this thesis was on the mechanisms of dynamic interaction between
the tumor cells and certain components of the tumor microenvironment (CAFs, immune
cells) in esophageal cancer. This was prompted by previous research performed by the
Rustgi lab members, as well as other publications.
The tumor cell – CAF cross-talk
Our lab has a long-standing interest in the role of stroma, particularly CAFs, in
esophageal carcinogenesis. For example, our lab reported a pro-invasive induction of
cathepsin B in ESCC cells, which was induced by a fibroblast-secreted factor (Andl et
al., 2010). Another report from our lab elucidated the mechanism where fibroblastderived HGF promotes invasion of ESCC cells into the ECM via activation of Met
receptor signaling within the ESCC cells (Grugan et al., 2010). Furthermore, research
from our lab identified the matricellular protein periostin as a stroma-derived factor
essential for invasion of ESCC cells into the ECM (Michaylira et al., 2010). Finally, a
recent report from our lab has focused on the function of another matricellular protein –
SPARC – in stromal expansion and metastasis in a murine model of pancreatic cancer
(Heeg et al., 2016). Not surprisingly, when we investigated the impact of co-culture with
CAFs on gene expression in ESCC cells, we found the genes encoding periostin,
SPARC and HGF to be strongly upregulated in response to interaction with fibroblasts
(Chapter 2, Figure 1a).
As described in detail in Chapter 2, we chose to study the dynamic interaction
between CAFs and tumor cells in the esophageal cancer microenvironment, focusing on
IL-6 and RANTES, the cytokines that mediate (at least partially) this interaction. While in
this thesis we focus mainly on the role of tumor cell-derived cytokines, it is essential to
95

keep in mind that, in addition to the mechanisms described herein (regulation of tumor
cell invasion, proliferation and apoptosis), IL-6 and RANTES are likely to be promoting
tumorigenesis in many other ways. Such mechanisms can include resistance to chemoand radiotherapy, expansion of reactive stroma, lympho- and angiogenesis, induction
and

maintenance

of

chronic

inflammation,

as

well

as

formation

of

an

immunosuppressive microenvironment (addressed, in part, in Chapter 3). Accompanied
by their roles in such quality-of-life-affecting conditions as cancer cachexia (Narsale and
Carson, 2014) and cancer-related pain (Hang et al., 2013), these observations make IL6 and RANTES attractive targets for cancer therapy. We provide in this thesis evidence
of the anti-tumorigenic effects of treatment with tocilizumab or maraviroc in vivo (Chapter
2, Fig. 6,8) and the superiority of combination treatment, compared to either drug alone,
in vitro (Chapter 2, Fig. 9). We believe that this approach would bring improved survival
and quality of life to esophageal cancer patients..
Cross-talk between MDSCs and tumor cells or CAFs
The interest in myeloid-derived suppressor cells and their role in ESCC was
sparked by the fairly unexpected results of investigating the changes in immune cell
populations in response to tumor progression in the L2-cre;p120f/f mouse model of
ESCC (Stairs et al., 2011). One of the most pronounced features of tumor-bearing L2cre;p120f/f mice was splenomegaly, and upon immunophenotyping of these splenocytes,
the only population that significantly expanded in response to tumor progression were
the CD11b+Gr-1+ MDSCs. We set out to determine the genes that could be
mechanistically linked to alternative differentiation of normal immature myeloid cells into
MDSCs in tumor-bearing animals, and identified Cd38, a gene encoding a cell surface96

expressed ectoenzyme receptor (Karakasheva et al., 2015). As described in detail in
Chapter 3, we proceeded to identify a panel of cytokines, specifically IFNᵧ, TNFα, IL-6,
CXCL16, IGFBP-3 and RANTES, that are responsible for the induction of CD38
expression by MDSCs in ESCC. Importantly, these cytokines can be produced by
multiple components of the TME. For example, IL-6 and RANTES, which are a major
focus of this thesis, are known to be secreted by the tumor cells, CAFs, immune cells, as
well as endothelial cells and adipocytes. CXCL16 can also be produced by CAFs
(Allaoui et al., 2016) and dendritic cells (Matloubian et al., 2000), while IGFBP-3 can be
produced in the liver, kidney and smooth muscle (Ranke, 2015). These facts suggest the
existence of intricate signaling networks that regulate the processes contributing to the
maintenance of immunosuppressive microenvironment, including the expansion of
CD38+ MDSC population.
Future perspectives
The findings presented in this thesis demonstrate the potential of disrupting the
interaction between tumor cells and stromal components (CAFs, MDSCs) for cancer
therapy. Furthermore, in many cases this can be achieved by repurposing of drugs
already in the clinic: tocilizumab, maraviroc and daratumomab have already been
extensively tested and approved by the FDA, which should dramatically simplify the
translation of our findings from the bench to the bedside.
Although the therapeutic approaches investigated herein resulted in significant
decreases in tumor growth rates, neither was capable of completely eliminating the
tumor. Therefore, future breakthroughs in cancer therapy will likely depend on
improvements in drug design and combination therapies. In addition to the combination
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of tocilizumab and maraviroc proposed in Chapter 2, it is reasonable to expect that
addition of conventional chemo- or radiotherapy to this treatment scheme could provide
improved outcomes. At the moment, a new generation of IL-6Rα targeting antibodies is
being rationally developed in such a way so as to specifically block IL-6 trans-signaling,
which is considered to be more relevant to carcinogenesis (Hunter and Jones, 2015). In
contrast to targeting the receptors, it could be beneficial to target downstream
components of the signaling pathways these receptors activate, such as combining
small molecule inhibitors of STAT3 and MEK/ERK as described in Chapter 2. This
approach can decrease the opportunities of cancer cells to acquire resistance to
targeted therapies, as well as potential compensation by other cytokines in the TME.
Finally, CD38-targeted therapy could also benefit from a combination with cytotoxic
drugs or radiation: these approaches are known to activate CD8+ T cells, which would in
this case cease being suppressed by MDSCs and proceed to clear tumor cells.
We are also looking forward to expanding our findings from Chapter 2 onto other
types of cancer. Based on published research and in silico analyses of gene expression
profiles from the TCGA database, it is evident that the relevance of both IL-6 and
RANTES spans beyond esophageal cancer: breast cancer (including the most
aggressive triple-negative subset), KRAS-mutant lung cancer, and colon cancer are
taking advantage of signaling induced by these cytokines. Therefore, we plan to test the
targeted therapies evaluated in this thesis in murine models of non-GI cancers.
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In regard to the basic science aspect of the research presented herein, many
things remain to be investigated. For example, while in Chapter 3 we defined a subset of
MDSCs (CD38high monocytic MDSC) that is more immunosuppressive than the total
MDSC population; this does not diminish the functional impact of granulocytic MDSCs
on cancer progression. We are working on developing a murine model that would allow
us to distinguish more accurately between the roles that each MSDC subset plays in
carcinogenesis. This model utilizes the “suicide gene” methodology by driving
expression of the herpes simplex virus thymidine kinase under either the Ly-6C or Ly-6G
promotor. Administration of ganciclovir to these animals will result in specific depletion of
monocytic or granulocytic MSDCs, respectively. In addition, given the differences
between murine and human immune systems in general, and the myeloid compartment
in particular, it would be extremely interesting to investigate the role of CD38 in the
biology of MDSCs from human cancer patients.
So far, our research described in Chapter 2 has been focused on the function of
tumor cell-derived cytokines. Yet, the mechanism through which CAFs in the TME
induce the tumor cells to secrete those factors (Fig. 1) remains to be elucidated. It is
likely that multiple factors, both soluble and membrane-bound, regulate this process.
Identifying these factors would be of utmost importance, since they can also be utilized
as targets for cancer therapy.
In conclusion, this thesis provides novel insight into the mechanisms of dynamic
interaction, or cross-talk, between the tumor cells and two components of the TME
(CAFs and MDSCs) in esophageal cancer. Interestingly, the findings from both Chapters
2 and 3 demonstrated the importance of the same two cytokines – IL-6 and RANTES –
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in these processes. We have also evaluated a number of novel therapeutic approaches,
all of which proved to be effective in our murine models of ESCC. We propose that these
approaches, individually or in combination, might improve existing approaches to cancer
therapy by disrupting the complex signaling networks in the tumor microenvironment.
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Figures and figure legends
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Figure 1
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Figure 4-1: Model. Chronic inflammation leads to activation of normal fibroblasts and
their conversion into cancer-associated fibroblasts (CAFs). CAFs acquire a new
secretory profile, producing pro-tumorigenic cytokines, including IL-6 and RANTES.
CAFs also interact with the tumor cells directly and alter their gene expression profile,
enabling tumor cells to secrete high levels of IL-6 and RANTES. These two cytokines
activate corresponding receptors (IL-6Rα and CCR5) on both tumor cells and CAFs in
an autocrine-paracrine manner, which results in activation (to a different extent) of the
STAT3 and ERK signaling pathways. These events result in increased tumor cell
proliferation, decreased apoptosis, increased invasion and promotes overall tumor
growth. IL-6 and RANTES also contribute (via induction of CD38 expression) to
alternative differentiation of normal immature myeloid cells (IMCs) into functional
myeloid-derived suppressor cells (MDSCs), which establishes an immunosuppressive
microenvironment within the tumor by suppressing the cytotoxic T cells (CTLs), and
therefore contributes to increased tumor growth.
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Chapter 5 APPENDIX: list of abbreviations
ADPR

Adenosine diphosphate ribose

ARG1

Arginase 1

Breg

Regulatory B cell

cADPR

Cyclic adenosine diphosphate ribose

CAF

Cancer-associated fibroblast

CCL5

C-C motif chemokine ligand 5

CCR5

C-C motif chemokine receptor 5

CRP

C-reactive protein

CTL

Cytotoxic T lymphocyte

CXCL16

C-X-C motif chemokine ligand 16

CXCR6

C-X-C motif chemokine receptor 6

EAC

Esophageal adenocarcinoma

ECM

Extracellular matrix

ESCC

Esophageal squamous cell carcinoma

FACS

Fluorescence-activated cell sorting

GERD

Gastroesophageal reflux disease

GPCR

G-protein-coupled receptor

HGF

Hepatocyte growth factor

HNSCC

Head and neck squamous cell carcinoma

IFN

Interferon

IL-6

Interleukin-6

IL-6R

Interleukin-6 receptor

iNOS

Inducible nitric oxide synthase

JAK

Janus kinase

mAb

monoclonal antibody

MAPK

Mitogen-activated protein kinase

MCP-1

Monocyte chemoattractant protein-1

MDSC

Myeloid-derived suppressor cell

MM

Multiple myeloma

M-MDSC

Monocytic myeloid-derived suppressor cell
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MMP

Matrix metalloprotease

NAD

Nocotinamide adenine nucleotide

PMN-MDSC

Perimorphonuclear myeloid-derived suppressor cell

RANTES

Regulated on activation, normal T cell expressed and secreted

SPARC

secreted protein acidic and rich in cysteine

STAT

Signal transducer and activator of transcription

TAM

Tumor-associated macrophage

TAN

Tumor-associated neutrophil

TME

Tumor microenvironment

TNF

Tumor necrosis factor

Treg

Regulatory T cell
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